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85 INTRODUCTION 
This  study has  three  purposes  : 
1.  to  analyse  the  trends  in expenditure  on  pharmaceuticals  in  the  countries 
of  the  Community; 
2.  to describe  the  main measures  taken in  the different countries which may 
have  a  direct  or  indirect influence  on  expenditure  on  pharmaceuticals; 
3.  to  examine  the  underlying  objectives  of public intervention in this field 
and  identify when  different objectives  lead  to  the  same  or conflicting 
policies. 
The  report brings  together in Part  I  such  information as  could  be  obtained 
on  trends  in expenditure  on  pharmaceuticals  over  the period  1965-1975  and 
attempts  to  analyse  how  far  changes  in expenditure  can be  accounted  for  by 
changes  in prices,  by  changes  in volume  and  by  changes  in other variables. 
Part II is the description of  the  particular measures  considered  as  liable 
to  influence  the  trends  identified  above. 
While  comparisons  are made  between  the  trends  in aggregate pharmaceutical 
consumption  in  the different countries,  no  attempt  is made  to  compare  the 
prices  of  individual  products.  A different  type  of  study would  have  been 
needed  to  collect  and  analyse  information of  this kind. 
While  we  have  taken responsibility for  the  preparation of  the  report,  the 
design  of  the  study  and  the preparation of  the  questionnaire  (printed  in 
Annex1)  were  undertaken in collaboration with  a  committee  of  experts 
drawn  from  each  country  : 
BELGIUM 
DENMARK 
GERMANY 
FRANCE 
IRELAND 
ITALY 
M.  J.  COBBAUT 
Ministere  de  la Sante Publique,  Brussels 
Dr.  A.  HARRESTRUP  ANDERSEN 
Sankt  Lukas  Hospital,  Hellerup 
Dr.  P.  ROSENBERG 
Deutsches  Institut fur Wirtschaftsforschung,  Berlin 
Mme.  S.  SANDIER 
CREDOC,  Paris 
Dr.  P.  BRENNAN  MD.  FRCPI 
St.Vincent's Hospital,  Dublin 
M.  L.  SCOTTI 
5 LUXEMBOURG  M.  L.  ROBERT 
Inspection des Pharmacies,  Luxembourg 
NETHERLANDS  M.  H.  DE  LEEUW 
U.K.  Prof.  B.  ABEL-SMI~H 
Department  of Health  and  Social·Security,  London 
The  final  report which we  have  drafted has  been  seen  and  approved  by  each 
member  of  the  group. 
Each  expert  took responsibility for  completing  the questionnaire for his  own 
country.  In addition  this  report  has  been  greatly  improved  by  amendments 
made  at a'series of meetings  where  drafts  of  the  report were  presented  to 
the  committee  of  experts. 
B.  ABEL-SMITH 
P.  GRANDJEAT 
6 PART  I 
TRENDS  IN  PHARMACEUTICAL  CONSUMPTION  (1966-1975) 
A.  TRENDS  IN  PHARMACEUTICAL  CONSUMPTION  IN  RELATION  TO  NATIONAL  INCOME, 
GROSS  NATIONAL  PRODUCT  AND  THE  COST  OF  HEALTH  SERVICES 
To  what  extent  is  the  consumption  of  pharmaceuticals  increasing in  the 
different  countries  of  the  community  ? 
Has  expenditure  on  pharmaceuticals been  increasing  to a  greater  or  lesser 
extent  than expenditure  on all health services  and  than  the  gross  national 
product  or  national  income  ? 
Has  expenditure  on  prescribed pharmaceuticals been  increasing at  a  faster  or 
slower rate  than pharmaceuticals  bought without prescription ? 
How  far  is it possible  to identify causes  ? 
For  example,  how  far  are  the  trends  explained  by  changes  in quantity or 
changes  in price  ? 
These  are  among  the  questions  examined  in  this  chapter. 
THE  DEFINITION  OF  PHARMACEUTICAL  CONSUMPTION 
To  calculate  the  total costs  of  pharmaceutical  consumption,  it is necessary 
to  add  together  the  sales  of  retail pharmacies  of pharmaceutical products 
for  human  consumption  and  the  cost  falling on hospitals  of  supplying 
pharmaceuticals  both  to  in-patients  and  out-patients.  Strictly speaking, 
the  cost  to hospitals  should  include all  the  costs  of  the hospital  pharmacy 
departments.  If  the  full  cost  of dispensing pharmaceuticals  in hospitals 
were  excluded,  the  figures  for  different  countries would  not  be  comparable 
as  the  proportion of national  pharmaceutical  consumption  supplied both  to 
in-patients  and  out-patients by hospital pharmacy  departments differs  among 
the  countries  of  the  Community,  as  does  the  extent  to which hospitals 
obtain  their  supplies  from retail pharmacists. 
Retail  sales  of  pharmaceuticals  for  human  consumption  can be  divided  into 
those  sold  'over  the  counter'  without prescription and  those  sold  on 
prescription.  These  two  categories  do  not necessarily correspond  to  sales 
of  the  types  of products which  can be bought without prescription because 
health  insurance  schemes will pay  for  them or  reimburse  part of  the  cost. 
Moreover  what  can be  bought without prescription varies  in the different 
countries  of  the  Community. 
7 only Luxembourg  was  able  to provide  statistics of  pharmaceutical  consumption 
(by  health  insurance)  which  closely  conformed  to  this definition.  In  severru 
countries, it was  not  possible  to make  a  breakdown  between expenditure  on 
hospital pharmaceuticals  and  pharmaceuticals  supplied  out  of hospital with 
and  without  a  prescription.  The  limitations  of  the  figures  supplied  by  the 
different  countries  of  the  Community  are  set  out below. 
BELGIUM 
The  statistics available  include  only  the  cost  of proprietary products  and 
exclude  products  made  by  pharmacists.  They  do  not necessarily include  all 
use  of  proprietary products  by hospitals  and  some  products  used  for 
veterinary purposes  are  included.  Made  up  preparations  are believed  to 
amount  to  about  ten per  cent  of  the  cost  of proprietary products.  It is 
not moreover  possible  to make  a  division between pharmaceuticals  provided 
by  hospitals  and  those  provided  outside  as  the health insurance  statistics 
do  not  cover  all pharmaceutical  consumption. 
DENMARK 
The  figures  include  sales by  pharmacies  to  other pharmacies.  Among  non-
prescription drugs  are  included  about  five  per  cent  of  sales  of  pharmacies 
which  go  on  other  items  (vitamins,  nursing  requisites  and  other  items). 
IRELAND 
As  no  reliable statistics are  available  for  pharmaceuticals  supplied without 
a  prescription and  the  only  figures  for  prescribed drugs  are  confined  to 
the  population  covered  by  the  general medical  service  scheme  and  health 
insurance  which  had  risen to  about  85  per  cent  of  the  population by  1975, 
no  figures  are  included  in the  tables. 
FRANCE 
The  figures  exclude  the running  costs  of hospital pharmaceutical  departments, 
but  include  the  cost  of  the  actual pharmaceuticals.  Moreover  expenditure  on 
bandages  dressing etc.,  is  included  and  this  is believed  to  constitute about 
five  per  cent  of  the  total.  Reliable  information is not  available  on  sales 
of  pharmaceuticals without prescription and  this  has  been estimated 
20  %  of  total sales  for patients other  than in-patients.  The  total 
consumption of  pharmaceuticals  by  in-patients  in public  and  private hospitrus 
has  been estimated  on  the basis  of  the  accounts  of  these hospitals. 
GERMANY 
The  official statistics do  not  include  any  figures  for  total pharmaceutical 
consumption.  While  there  are  figures  for  the  total sales  of pharmacies,  a 
variety of  non-pharmaceutical  products  are  sold  by  them.  Estimates  of  sales 
of  pharmaceutical products  in  other  shops  are  far  from reliable.  There  are, 
however,  statistics of medicaments,  therapeutic products  and medical  aids 
8 from  pharmacies  in the  compulsory health  insurance statistics but no  reliable 
information is available  on products bought without  a  prescription. 
Information  on  pharmaceutical  consumption in hospitals  is available  only 
from  1972  onwards,  and  it does  not  include  the  cost  of hospital dispensing 
departments. 
The  estimates  have  been pieced  together  by  attempting  to reconcile  such 
sources  of  information as  are  available.  The  trend  figures  need  to be 
interpreted with particular caution as  certain percentage relationships 
been  assumed  to  be  constant over  the  period  covered  by  the  statistics. 
attempt  has  been made  to  include  the  cost of hospital dispensaries. 
ITALY 
have 
No 
The  figures  for  pharmaceutical  consumption in hospitals  include  the  cost of 
hospital pharmacists  and  their assistants but not other  costs  of hospital 
pharmaceutical departments.  Hospital  pharmacies  are entitled to purchase 
proprietary products  under  the  law  at special discount prices which 
amounted  to  at  lea's\t  SO  %from 1,974  onwards in the  case  of  the vast majority 
of  products.  Similarly discounts  are  allowed  on  pharmaceuticals  supplied 
under  the  health service  outside hospital  of  17  per  cent up  to August 
1970  and  25  % thereafter.  In  the first  case  consumption  is  shown  after 
discount  and  in  the  second  case before discount. 
LUXEMBOURG 
As  until  1977  all hospitals  purchased  their pharmaceutical  supplies  from 
retail pharmacists,  it is not  possible  to  identify separate  consumption by 
hospitals. 
NETHERLANDS 
The  figures  cover  only prescription drugs  used  outside hospital.  Reliable 
figures  for  drugs  used  in hospitals  or  obtained without prescription are 
not  available. 
UNITED  KINGDOM 
The  figures  cover England  and  Wales  and  are  for  financial  years.  The 
figures  for  private expenditure  outside hospital  cover  'medicines,  lotions, 
surgical  goods,  dressings  and  appliances'  and  are  subject  to  a  sampling 
error  of  roughly  £  10 million.  The  figures  for  the National Health  Service 
non-hospital  consumptioninclude dressings  and  appliances which  amount  to 
about  five  per  cent  of  the  total expenditure.  Pharmaceuticals  in private 
hospitals  are  not  included but  this  sector is very  small.  The  figures 
for  national health service hospitals exclude dressings  and  appliances,  but 
do  not  include  pharmaceutical  department's  staff costs  and  overheads.  All 
private expenditure  is classified  as  not  on  prescription  though  a  small 
proportion was  prescribed  in private practice  outside  the National  Health 
Service. 
9 Thus  the  most  important  points  to bear  in mind  in interpreting the  figures 
are  : 
1.  No  figures  are  available  for  Ireland. 
2.  Only  the  figures  for  Luxembourg  include  the whole  cost  of hospital 
pharmaceutical departments,  though  those  for  I.taly include  the  cost of 
hospital  pharmacists  and  their assistants. 
3.  There  are  no  estimates  available  for  non-prescription drugs  in the 
Netherlands.  Percentage  relationships  have  been used  to estimate  the 
trend  of  sales  of non-prescription drugs for  France  and  Germany.  The 
figures  for  Denmark  and  the  U.K.  (England  and  Wales)  contain  some  items 
other  than pharmaceuticals. 
4.  The  Belgium figures  exclude  preparations made  up  by pharmacists. 
The  figures  for  total  consumption  of  pharmaceuticals  can be  shown  including 
or excluding  tax.  The  tax rate  on  pharmaceuticals has  varied  over  the 
period  covered  by  this  study  in the  different countries  of  the  Community. 
The  rates. as  at  1966  and  1975  are  given below.  In  the  case  of France  and 
the  United  Kingdom  higher  rates  of  tax were  at  some  time  charged  between 
these  two  years  than  the  figures  shown  for either year. 
1966 
Belgium  6  % 
Denmark  Nil 
France  16.08  % 
:Lreland  Nil 
Germany  Nil 
Italy  5.2  % 
Luxembourg  Nil 
Netherlands  0  % Prescription drugs 
6  % Over  the  counter 
drugs 
U.K.  Nil 
1975 
6  % 
15  % (9  % from  late  September) 
6.54  % 
Nil 
10  % 
20  % 
11  % 
5.65  % 
2  % 
5  % 
4  % 
18  % 
8  % 
Taken  by mouth 
Injections 
Antiseptics 
Drugs 
Dressings 
Prescription drugs 
Over  the  counter drugs  (from 
1.10.1976) 
Except  when  supplied by  a 
pharmacist  against  a  doctor's 
or dentist's prescription. 
The  estimates  of  total pharmaceutical  consumption  including  tax are  shown 
in Table  1  as  a  percentage  of  gross  national  product. 
There  appear  to be  wide  variations  in the role  of pharmaceutical  consuption 
in the  different  countries  of  the  Community. 
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 In France  and  Italy, pharmaceutical  consuption  in  1975  was  between  1.5  and 
2  % of  gross  national product,  and  in Belgium and  Germany  it was  between  1 
and  1.5  % of  gross national product  and  just over  1  % in Luxembourg. 
In Denmark  and  United  Kingdom  in the  same  year,  pharmaceutical  consuption 
amounted  to 0.66  and  0.75% of  gross national product  respectively. 
Only  in the  United  Kingdom  (England  and  Wales)  was  total  consuption of 
pharmaceuticals  a  slightly lower proportion of  gross national product  1975 
than in 1966.  In Luxembourg  no  clear  trend  upward  or downward  can be  seen 
in the  relationship between pharmaceutical  consumption  and  gross national 
product.  In  the  other  countries  the  figures  show  a  slight if uneven  trend 
towards  an  increasing proportion of  gross  national product being devoted  to 
pharmaceutical  consumption. 
Total pharmaceutical  consuption excluding  tax is  shown  in Table  2  as  a 
percentage  of  national  income. 
The  results  are  similar  to  those  for  Table  1  except  that  there  is no  longer 
an  upward  trend  in  the  case  of France  and  there  is  less  of  an  upward  trend 
in the  case  of  Belgium,  Denmark  and  Germany.  This was  due  to  the 
introduction of  Value  Added  Tax  in  1968  in  the  case  of  Germany. 
In Table  3  the  estimates  of  total pharmaceutical  consuption  (including  tax) 
are  shown  as  a  percentage  of  the  estimates  of  the  total current  cost  of 
health services  (including  tax). 
The  estimate  of  the  current cost  of health  services  used  are  those  presented 
in the  study  of  the  cost  of health care  (1)  and  are  subject  to  the  important 
qualifications  set out  in that study.  The  most  important  identified 
reasons  for  non-comparability  are  the  following 
1)  The  figures  for  Belgium include  some  capital costs  and  the  figures  for 
the  other  countries exclude  them. 
2)  The  figures  for  Luxembourg  are  for health  insurance  service  only. 
3)  The  cost  of  the depreciation  of hospital buildings  is  included  in  the 
figures  for  France,  the Netherlands  and  partly in  those  for  Belgium,  but 
not  in  those  for  the  other  countries. 
4)  The  figures  for  Germany  are  based  on  imperfect  semi-official estimates 
for  the  two  years  1968  and  1972.  The  figures  for  the  other years  are 
estimated  on  the basis of  trends  in  the  expenditure  of  the health 
insurance  schemes. 
5)  The  figures  for  the  Netherlands  exclude non-prescription drugs  and  those 
for  Italy include  only registered medical  products  obtained without 
prescriptions. 
(1)  B.  ABEL-SMITH  and  A.MAYNARD  :  "The  organization,  financing  and  cost  of 
health-care  in  the  European  Corrnnunity". 
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 There  are  remarkably  large variations  in the  role which  pharmaceuticals  play 
in total health expenditure  in the different countries  of  the  Community. 
The  variations  are  too  large  to be  wholly explained  by  the  non-comparability 
of  the  figures both for  pharmaceutical  consumption  and  for  the  cost  of  health 
services.  The  figures  for  1975  show  a  variation from  about  11  % of  the  cost 
of health services  in Denmark  (1974)  and  about  14  % in the  United  Kingdom  to 
around  25  % in France  to  36  % in Italy.  Some  of  the  reasons  for  the variations 
are  analysed  later in  this  chapter. 
In all countries  in  the  Community  for which  figures  are  available,  there  is 
a  clear  downward  trend  in  the  proportion  of  total expenditure  on  health 
services  devoted  to pharmaceutical  consumption.  Over  the  period  1966  to 
1975,  the  proportion dropped  in Italy from  nearly 54%  to  36  %.  The  figures 
for  Belgium  show  a  drop  in percentage  over  the  three  years  1973  to  1975 
from  27.3%  to  19.5  %.  The  fall  in the  percentages  between  1966  and  1975 
was  less  marked  in France  (29.7%  to  25.5  %),  Germany  (22.8%  to  17.6  %), 
the  United  Kingdom  (from  18%  to  13.8  %)  and  Denmark  (15.7%  to  11.1  %). 
Few  countries were  able  to dividepharmaceutical  consumption with reasonable 
reliability into non-prescribed medicines,  prescribed medicines  in hospital 
and  prescribed medicines  given outside hospital.  But  all estimates  given 
for  non-prescribed medicines  showed  them  as  a  declining share  of  the  total 
pharmaceutical  consumption.  For  example,  the  figures  for  the  United  Kingdom 
(excluding  tax)  indicate  a  decline  from  about  31  % of  the  total  in  1966  to 
about  23  % in 1975.  Similarly in Denmark  the  decline  was  from  about  20% 
in 1966  to  14  % in  1975.  All  the  countries with reasonably  reliable data 
showed  a  rising proportion of  total pharmaceutical  consumption  in hospitals 
between  1966  and  1975. 
In Table  4  total  consumption  of  prescribed medicines  (in or  out  of hospital) 
is  shown  as  a  proportion of  the  total cost  of health  services.  The  trend 
is  downwards  for  all countries providing date. 
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 B.  THE  ANALYSIS  OF  TRENDS  IN  THE  COST  OF  PHARMACEUTICAL  CONSUMPTION 
Pharmaceutical  Consumption  in constant prices 
Special price  indices  for  pharmaceuticals,  based  upon  a  'basket'  of  a  number 
of  products,  are maintained  in seven countries  in the  Community.  The 
products  included  in  the  index may  be  changed  over  the  years.  Such  an  index 
can only give  an  imperfect  indication in  the  trend  of  pharmaceutical  prices 
because  of  the  substantial rate of  innovation in the  pharmaceutical  industry. 
A new  product  may  replace  an older product  as  the most  commonly  used treatment 
for  a  particular condition.  This  new  product may  be  launched  at  a 
substantially higher  price  than  the  product it is replacing.  This 
'replacement effect'  is not fully reflected in price  indices based  on baskets 
of  goods.  Changes  in volume  are  due  to  the  combined  effect  of  changes  in 
both quantity  and  quality. 
The  seven  indexes  are briefly described below 
DENMARK 
A retail index  is  available based  on  105  products  of which  72  were  available 
only  on  prescription.  New  drugs  are  introduced  into  the  index.  The 
underlying weights  were  last  changed  in February  1969.  The  index is of  final 
prices  and  includes  VAT  and  the  pharmacists'  margin.  For  this  reason  the 
wholesale  price  index is used  in this  study. 
GERMANY 
The  index is based  on  33  made  up  products  which were  given 88  % of  the 
weight  of  the  index in 1970.  The  remaining  12  % of  the  index  covered 
non-pharmaceutical  products  sold  in pharmacies  (e.g.  cosmetics,  dressings  and 
disinfectants).  New  products  have  been  introduced  to  the  index  as  old 
products  are  no  longer  sold  on  the market. 
IRELAND 
The  index is based  on  85  items,  six of which  are  available without 
prescription.  New  products  are  introduced  to the  index  as  they  become 
extensively used  and  older  products  are  discarded  as  their use  drops. 
FRANCE 
The  index is based  on 400  products  of which  300  are  reimbursable by health 
insurance  and  100  are  products  on  sale  to  the public. 
ITALY 
The  index  is based  on  31  proprietary products  some  of which  were  introduced 
during  the  ten-year period. 
17 NETHERLANDS 
The  index included  products  which  cover  80  % of  the  consumption  o£ 
prescribed drugs.  The  index is weighted  every year by  the  sales  of  each 
product  included  (chain weighted). 
UNITED  KINGDOM 
The  index is based  on wholesale  prices,excluding tax,of  200  closely defined 
pharmaceutical  preparations weighted  according  to sales.  The  weights  are 
periodically revised.  It includes  some  non-prescription items. 
In Table  5  the  seven price  indices  are  compared  with  the  retail price 
indices  for  the  same  country. 
In Germany  and  Denmark  there has  been little difference  in the  two  indices. 
In  the  other five  countries,  the  pharmaceutical  price  index has  risen 
substantially less  than  the retail price  index.  The  difference  is 
particularly marked  for  France  where  pharmaceutical prices  rose  just over 
18  per  cent between  1966  and  1975  compared  with  a  rise  of  nearly  84  per  cent 
in retail prices. 
As  mentioned  earlier, what  indices  constructed  from  a  basket  of  products  do 
not  record  is  the  replacement effect which  is very  important  in 
pharmaceuticals  and  an  important  reason  for  rising costs.  The  quantitative 
effect of  this  can be  seen by  comparing  the  trend  in the  average  cost of  an 
item in  a  prescription with  the  trend  in retail prices  and  the  trend  in the 
pharmaceutical price  indices described  above.  In making  this  comparison it 
should  be  borne  in mind  that  one  possible  reason for  a  change  in  the  average 
cost  of  a  prescription item may  be  a  change  in the  amount  prescribed. 
Comparisons  of  this kind  can be  made  for  three  countries  as  shown  below. 
Percentage  Increase  1966  to  1975 
Retail  price Pharmaceutical price Prescription 
index  index  Item 
France  183.7  118.3  164.5 
Italy  (1976)  233.2  154.2  180.9(1) 
United  Kingdom  222  161  257  (2) 
(1)  Under  the  INAM  scheme. 
(2)  Ingredient  cost  in England  & Wales. 
In Table  6  total pharmaceutical  expenditure excluding  tax is  shown  in 
constant  prices using  the  above  pharmaceutical price  indices  even  though 
they  are  not  wholly  appropriate  for  this  application. 
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 Between  1966  and  1975,  total pharmaceutical  consumption  rose  by  about 
80  %  in  Germany  (53  % from  1968)  and  by  67  % in the 
United  Kingdom  (England  and  Wales)  and  only  41  % in Denmark.  The 
growth  in France  and  Italy was  much  greater at nearly  156  % and 
over  135  %  respectively.  In  the  case  of  the  Netherlands  expenditure  on 
drugs  prescribed  out  of hospital  rose  by  69  %between  1970  and  1975. 
Estimates  of  pharmaceutical  consumption  (excluding  tax)  per  head  of 
population in constant  and  current prices  are  shown  in Table  7.  Real 
expenditure per head  more  than doubled  over  the  period  in both France 
and  Italy.  The  growth was  61  % in England  and  Wales  and  only  33  % 
in Denmark. 
In Table  8  is  shown  expenditure  (excluding  tax)  per  head  at  constant  prices 
of  the population  covered  by  health  insurance. 
The  Extension  of  Health  Insurance 
In  some  countries,  the  extension of  the  coverage  of health  insurance  has 
been  a  factor  leading  to  an  increase  in pharmaceutical  expenditure  over  the 
period.  The  change  is  shown  in Table  9. 
TABLE  9 
The  Coverage  of Health  Insurance  or Health  Services  in 1966  & 1975 
(includes voluntary members  of  the  main health  insurance  schemes) 
(in % of  total population) 
Belgium 
Denmark 
Germany 
Ireland 
France 
Italy 
Luxembourg 
Netherlands 
United  Kingdom 
1966 
75 
90-95 
85.6 
39  (1) 
93.6 
85  (2) 
100 
70 
100 
1975 
85 
100 
90 
85  (1) 
98 
94 
100 
70  (3) 
100 
(1)  Coverage  varies  for  different benefits.  The  figures  quoted  are  for 
hospital  care when  coverage  is highest. 
(2)  Only  about  3/4  of  the  insured  population were  entitled  to pharmaceutical 
benefits. 
(3)  By  1975  the  whole  population was  covered  for  long-stay hospital  care. 
23 In  Italy not  only was  there  an  increase  in the  numbers  entitled  to 
pharmaceutical benefits,  but  another  cause  of  the  rise in expenditure was 
the  transfer  in 1970  of  6.8 million persons  from  the  reimbursement  system 
to  the  direct  payment  system.  This  group  thus  added  to  the  number  of 
workers  (33  million)  already receiving direct benefits. 
Variations  in Pharmaceutical  Consumption by Characteristics  of  the 
Population 
The  change  in  the  demographic  compos~t~on of  the population has  been  one  of 
the  reasons  for  rising pharmaceutical  consumption.  There  is evidence  from 
a  number  of  countries  that  consumption per head  is  substantially higher  for 
the  aged  than  for  those  below  pension  age.  The  proportion of  aged  has  been 
increasing in all countries  of  the  Community. 
In  Belgium pharmaceutical  expenditure  paid  for  by  the  health insurance 
scheme  was  over  three-and-a-half  times  greater  among  the  aged  than  among 
healthy  adults  of working  age  in  1975.  The  consumption rate of  invalidity 
pensioners  was  similar  to that  of  the  aged.  In Germany  consumption  of 
pharmaceuticals  was  also over  three-and-a-half  times  greater under  the 
pensioners health  insurance  scheme  than  under  the  general  scheme.  In 
England  and  Wales  the  difference  in consumption between adults  under  pension 
age  and  those  of  pension  age  was  much  less marked  - those  of pension age 
cost  less  than  twice  the  amount  of  adults  under  pension  age. 
In France  a  Credoc  Survey  (1)  of  the consumption of pharmaceuticals  by  narrow 
age  groups  conducted  in 1970  showed  that  the  lowest  consumption  of 
pharmaceuticals was  found  in the  age  group  10-19 where  it was  40  % 
of  the  average.  Consumption  in the  age  group  0-3  was  34  % above  the 
average  and  consumption  rose  steadily with  age  from  those  aged  10-19  to 
reach  a  peak  in the  age  group  70-79 where  consumption was  112  % 
above  the  average  for  all age  groups. 
The  same  study  showed  that  the  consumption  of non-prescription drugs 
increased with  the  socio-cultural  level  of  the population.  In  the  case  of 
prescribed drugs  only  small variations were  found  with  socio-professional 
category,  household  income  and  level  of  educational  attainment  of  the  head 
of  household.  A markedly  lower  use  of pharmaceuticals was  found  among 
farmers  and  farm workers.  A marked variation by  family  size was  also found 
- the  larger  the  family  the  smaller  the  consumption per  family  member. 
Moreover  the  larger  the extent  of private insurance,  the  greater  the 
utilisation of  prescribed drugs. 
(1)  A.  A.  Mizrahi  and  S.  Sandier,  'Demographical Factors  and  the  Growth  of 
Pharmaceutical Consumption'.  Consumption N°l  1974. 
24 Changes  in charges  or  proportion of  cost not  reimbursed 
Also relevant has been  the extent  to which  charges  are  levied  for 
pharmaceuticals under health insurance  schemes.  Here  there  is  a  wide 
variation in the different  countries  of  the Community  and  arrangements 
have  been  changed  during  the  period  studied here.  The  systems  of  charging 
are described  in lie. 
The  ConsultationRate  and  the Prescribing Rate  per Consultation 
One  possible explanation for  the very wide  differences  in the  role  of 
pharmaceutical expenditure  in total health expenditure  among  the different 
countries  of  the  Community  may  be variations in the extent  to which 
patients  consult  their doctors  and  the  extent  to which  consultations result 
in a  prescription of  one  or more  items. 
Only  a  tantalisingly limited  amount  of  information was  available  on  these 
questions.  In Belgium visits  and  consultations  rose  from  5.3  to  6.3  per 
annum  per  insured  person between 1966  and  1975.  Under  the  general  INAM 
scheme  in Italy visits per  insured  person by  doctors  paid  on  a  fee-for-
service basis  (who  provided  services  to about  a  third  of  those  insured 
under  the  scheme)  rose  from  9.2  per  annum  in 1966  to neraly  11.5  in 1975. 
In England  there  are  no  comprehensive  statistics but  a  national  survey 
suggests  a  consultation rate of  about  three-and-a-half per  person per year. 
In Germany  the  consultation rate was  estimated for  1976  as  12  per  person 
per year. 
In Eire  over  80  % of  consultations  und~r the  General  Medical  Service 
Scheme  result in  a  prescription.  Under  the  'Regime  General'  in France 
75  %,  of consultations resulted  in a  prescription in 1972. 
The  average  number  of prescription items  provided  per  person per year  is 
shown  in Table  10. 
TABLE  10 
Prescription items  per  person per year 
1966  1970  1973  1974  1975  1976 
Belgium  9  - - - 9  -
Denmark  - 6·2  - - - 6.9 
Germany  - - 11  - - -
Ireland  (1)  9  - - - 10  -
France  - - - - 10.50  -
Italy  (2)  13  - - - 21  -
Netherlands  - - - 4.5  - -
United  Kingdom  (England  and  Wales'  5. 7  - - - 6.3  -
(1)  Under  General Medical  Service  Scheme. 
(2)  For  doctors  paid  on fee-for-service basis  under  INAM. 
25 The  latest figure  for  each country is shown  in Table  11  with  the  percentage 
of  the estimated  cost  of health services devoted  to pharmaceutical 
consumtion  from  Table  3. 
TABLE  11 
Doctors  per  10.000 population,  average  prescription items  per person per 
year,  and  pharmaceutical  consumption  as  a  proportion of  the  cost  of health 
services. 
Doctors  per  Prescription  Items  Pharmaceutical 
10,000  Per  Person per  year  under  Consumption  as 
population  Health  Insurance  or  the  a  Percentage  of 
(1)  Health  Service  Cost  of Health 
Services 
(1975)  (1975)  (1975) 
Netherlands  16.0  4.5  (1974)  9.5  (2) 
United  Kingdom 
(England  and  Wales)  13.1  6.3  13.8 
Denmark  16.2(1972)  6.9  (1976)  11.7  (1974) 
Belgium  (3)  18.9  9  19.5 
France  (3)  14.7  10.5  25.5 
Germany  19.4(1974)  11  (1973)  18.8  (1974) 
Italy  (3)  19.9(1973)  21  (4)  34.6 
(1)  Sources- WHO,  Annual  Statistical  Summaries  1965  and  1977. 
(2)  Only  covers  prescription drugs  outside hospital. 
(3)  Including doctors  practicing dentistry of  specialists in odontology. 
(4)  For  doctors  paid  on  fee-for-service  basis  under  INAM. 
The  very  large variations  in  the  average  number  of prescription items  per 
person per  year  appear  to  go  a  considerable way  towards  explaining  the  wide 
differences  in  the  role  of  pharmaceutical  consumption  in the  cost  of health 
services  in  the different  countries  of  the  Community.  It would  be  of 
considerable  interest to  see  how  far  the  differences  in  the  number  of 
prescription items  are  due  to differences  in morbidity  or differences  in the 
extent  to which  doctors  use  pharmaceuticals  for  particular conditions. 
There  does  not  appear  to be  a  relationship between  the  number  of  doctors 
per  10,000 population and  the  rate  of  prescribing.  It is however 
noticeable  that  in the  three  countries with  the  lowest  average  number  of 
prescription items  per  year  general  practitioners were  not  paid  on  a  fee-
for-service basis  under  the  compulsory health insurance  of  health  service 
scheme,  while  in all  the  countraies with  a  high  average  number  of 
prescription items  doctors  were  paid  on  a  fee-for-service basis.  This 
finding warrants  further  examination.  For  example,  it would  be  necessary  to 
see  how  far  variations  in items  prescribed  in different  countries  are 
affected  by what  is  covered  by different health  insurance  (or  service) 
systems,  by  the  size  of  available packages,  by  restrictions  on  the duration 
of  prescriptions  and  by  the  extent  to which mixtures  of  products  are 
available  (for example  two  prescription items  may  be  needed  in one  country 
to  provide what  can be  provided  in one  prescription item in another). 
26 Reasons  for  the  Increase  in Cost 
The  reasons which may  explain the  changes  in cost  can be  summarised  as 
follows  : 
i.  Increase  in the population. 
ii.  Increase  in the  coverage  of  Health  Insurance  and  also,  in the  case  of 
Italy,  a  transfer  of  a  section of  the  population  from  reimbursed 
benefit  to direct  service benefits. 
iii. The  changing  age  structure of  the  population. 
iv.  Changes  in  the  cost  of  production  and  distribution. 
v.  The  replacement  of older  drugs  by  more  expensive  new  drugs  and  their 
acceptance  in social security  (in those  countries where  social 
security controls what  may  be  accepted). 
vi.  Changes  in  the  consultation rate. 
vii.  Changes  in  the  prescription rate per  consultation. 
viii.  Changes  in the patterns of disease. 
ix.  Changes  in therapeutics. 
x.  Increasing sales pressure  on  doctors  by  the  pharmaceutical  industry. 
xi.  Growing  public education,  changing attitudes  to  illness  and  belief in 
the  therapeutic value  of  pharmaceuticals which  are  expected,  if not 
demanded. 
In  a  number  of  countries  attempts  have  been made  to analyse  in quantitative 
form  the  causes  of  the  increase. 
In Luxembourg  it is calculated  that  about  40  % of  the  increase  is 
due  to higher prices  including the  replacement  of  old  products  by  new 
products  and  about  60%  due  to  the  number  of  items  prescribed. 
In Italy the  increase in cost is analysed  as  follows 
Increase  in number  of prescriptions  31.78  % 
Increase  in average cost per prescription  32.69% 
Increase  in population  3.02 % 
Interaction of  the  above  32.51 % 
100.00 % 
27 In France  an  analysis  for  the  period  1970  to  1975  in  terms  of  annual  growth 
rates  gives  the  following results  : 
Expenditure 
Population 
General Price  Index 
Expenditure  per  person at relative prices 
Number  of  consultations 
Number  of prescriptions per  consultation 
Average relative price per package 
12.7  % 
0.8  % 
8.8  % 
2.8  ·% 
2.9  % 
0  % 
3.0 % 
Thus  in France  the  change  in the  number  of consultations played  a 
considerable role  over  that period. 
An  analysis  for  England  and  Wales  produced  the  following results for  the 
period  1966  to  1975  assuming  that each factor  operated  in isolation 
Rise  in total population 
Age  structure of  the population 
Rise  in number  of prescription items per person 
(adjusted  for  changing  age  structure) 
Rise  in pharmaceutical price  index 
Rise  in the  average  cost per prescription 
(adjusted  for  the  price  index  and  changing  age 
structure of  the  population) 
+  3  % 
+  2  % 
+  11  % 
+  61  % 
+  60  % 
The  combined  effect of  the  above  is to multiply  the  cost by  three.  The 
actual  increase  in the  cost of  ingredients was  from  £  96  million in  1966 
to  £  286  mi Ilion in 1975  - very nearly  a  threefold  increase in cost. 
Forecast 
A forecast  has  been made  for  France  of  future  pharmaceutical  consumption. 
The  forecast  is based  on  the  analysis  of  trends  which  show  : 
i. The  average  number  of products prescribed  per  contact with a doctor 
(visit or  consultation)  has  been rising by  about  1  1/2  % per 
annum. 
ii. There  is a  greater  consumption  of  drugs  the  larger  the number  of visits 
to patients in their homes. 
iii. Specialists  and  doctors  working  in hospitals prescribe  less  than GPs. 
28 The  forecasts  show  that  the  total volume  of pharmaceutical  consumption will 
increase  from  9  to  11  % per  annum  between  1973  and  1980 but  the  number  of 
items  prescribed per  consultation will  increase at  the rate  of  5  to  6  % 
per  annum  because  of  a  decrease  in the  number  of drugs  prescribed per contact 
with  a  doctor  due  to  a  higher proportion of  contacts with specialists rather 
than GPs.  Taking  account  of  the  lowering  of  VAT  on  drugs,  the  relative 
value  of  drug  consumption will  increase by between  1.4  % and  2.9  % between 
1975  and  1980 which  is noticeably  less  rapid  than in the  previous  period 
(4.5  %per  annum). 
A forecast  has  also been made  for  England  and  Wales  of  the  cost  of 
pharmaceuticals  obtained with  a  prescription under  the National Health 
Service.  The  forecast  is based  on  past  trends  and  indicates  a  rise in 
constant  prices  from  £  420 million in 1976  to £ 523  million in 1980  - an 
increase  of nearly  27  % over  this  five-year  period. 
29 C.  FOREIGN  TRADE  IN  PHARMACEUTICALS  AND  RAW  MATERIALS 
Three  tables  (12,  13  and  14)  have  been drawn  up  and  will be  analysed  below. 
First, however,  some  preliminary remarks  are  necessary. 
The  first is  that  the  percentages  given - and  the  trends  emerging  from 
them  - must  be  viewed  with  care  and  caution.  They  are  rough  indicators 
which  are  not,  in all cases,  based  on  homogeneous  data.  Thus,  production, 
imports  and  exports  are  calculated at different prices  (FOB  or  CIF,  for 
example).  Secondly,  it has  been difficult to break  the  figures  on 
"pharmaceutical  products"  down  into products  for  human  consumption  and 
other products.  Germany,  Belgium,  Ireland  and  the  United  Kingdom  explained 
the  reasons  for  this,  but no  such  information was  offered  in the 
confirmation  obtained  for  the Netherlands  and  Italy. 
In  Ireland  and  Denmark  the percentages  of veterinary products  in  the  total 
of products  consumed  are,  respectively,  according  to estimates,  1.8  % and 
4.7  %. 
Only  the  French  reply  gives  these  percentages  at  three  levels 
Production  3.70 
Exports  6.90 
Imports  1.00 
The  third  remark  concerns  Luxembourg,  which  no  longer has  a  domestic 
pharmaceutical  industry. 
TABLE  12 
Exports  and  imports  as  percentages  of national production  (NP) 
Year  NP  Exports/NP  Imports/Np National  consump,tion 
percentage  of  NP 
Germany  1974  100  35.22  15.23  80.00 
Luxembourg  None 
Belgium  1975  100  43.25  50.41  107.03 
France  1975  100  21.84  15.60  93.80 
Ireland  1973  100  40.21  32.96  92.70 
United  Kingdom  1975  100  42.23  13.19  70.82 
Netherlands  (1)  1973  100  62.60  48.27  84.41 
Denmark  1975  100  59.71  34.78  75.08 
Italy  1975  100  20.60  19.80  99.20 
(1)  These  figures  relate only  to pharmaceutical products  and  not  to raw 
materials. 
30 
as In all  the  countries  under  consideration,  except  Luxembourg,  the 
pharmaceutical  sector  - finished  products  and  raw materials  - is  a  sector 
open  to  foreign  trade,  since  a  fair  and  sometimes  considerable  portion is 
always  accounted  for  by  imports  and  exports.  Furthermore,  the  third  column 
shows  the  significance  of  the  home  market  in each  country which  thus 
appears  to  parallel foreign  trade. 
TABLE  13 
Trade with  EEC  countries  as  percentage  of  total trade 
Exports  to EEC/  Imports  from EEC/ 
total exports  total imports 
Germany  34.44  51.21 
Luxembourg  90.00 
Belgium  62.84  68.52 
France  17.55  3.90 
Ireland  51.58  84.80 
United  Kingdom  27.10  49.57 
Netherlands  not  given  not  given 
Denmark  29.60  55.00 
Italy  30.90  62.70 
The  percentages refer  to  the  same  years  as  those  in table  12. 
The  volume  of  trade  in pharmaceuticals within  the  EEC  is quite  considerable, 
as will be  observed.  However,  it is hard  to attribute  this  to  a  single 
factor.  Compliance with  EEC  Directives by  the  various  countries  and  the 
adoption of  similar health criteria (safety for  use  and  efficacy)  seem  to be 
as  important  as,if not  more  important  than  any  specific legislation or  customs 
regulations  - as will be  seen  later under  X(A),A*. It is unlikely  that  any 
country in the  EEC  would  deny  itself the  use  of  a  drugofknown  therapeutic 
value  because  of its country  of  origin. 
It might  be  asked  whether  the  relatively  low  share  of French  and  British 
exports  consigned  to  other  EEC  countries  is not  a  result  of  the  substantial 
importance  of  these  States'  exports  to  countries previously under  their 
political control.  It would,  on  the  other hand,  be  wrong  to  ignore  the  fact 
that in certain European countries  (for  example  the  United  Kingdom  and 
Ireland)  the exporters  are  subsidiaries  of American  companies  or  are using 
their patents. 
:lifSee  Annex. 
31 It would  have  been desirable  to have  available  information  on  the 
respective shares  of  raw  materials  and  finished  products  in imports  and 
exports, which would  have  given  an  indication as  to  the value  added  in each 
country  and  the  exact nature of  the  production process.  However,  all the 
experts  thought  the data available  to be  too  fragmentary  and  untrustworthy 
for  any  conclusion  to be  drawn,  at  least in a  comparative  sense.  It was, 
therefore,  unanimously  agreed  not  to reproduce  them in this  summary  report. 
Finally,  in their reports  the  national experts were  asked  to  indicate,  as 
far  as  possible,  trends  in the  figures  for  trade during  the  past  ten years. 
Only  seven  countries were  able  to produce reliable statistics,  and  the 
period  covered was  not  always  identical;  in no  case was  it greater  than 
five years.  The  following  table  sets  out  the replies. 
TABLE  14 
National production  Exports  Imports 
Germany 
+  58.56  %  +  58.46  %  +  75.02  %  (70-74) 
Belgium 
+  117.35  %  +  178.04  %  +  85.50 %  (70-75) 
Denmark 
+  108.00 %  +  102.00 %  +  102.00  %  (70-76) 
Italy 
+  98.62  %  +  156.49  %  +  152.80 %  (70-75) 
Netherlands  34.00  %  34.00 %  (71-73)  - +  + 
France 
(70-75)  +  85.66  %  +  97.58%  +  61.79  % 
Ireland  +  120.10  %  +  141.65  %  +  61.49  %  (70-73) 
It is impossible  to make  any  comparisons  between countries  based  on  this 
table.  The  figures  have  been expressed at current  and  not  constant prices, 
i.e.  they  are  inflated by  the  price rises for  drugs  during  the period. 
Thus,  it is not surprising to  see  that  these  figures  for  the  increase in 
national production during  the  review period  are higher in France  and  Italy, 
where  inflation was  high,  than in Germany  and  Denmark,  where  price  increases 
were  very  limited.  It is interesting to note  that exports  from all the 
countries,  except  Germany,  increased  as  much  as  or more  than  natio~al 
production;  this  fact must  be  borne  in mind  when  considering whether  a 
price restraint policy has  the effect of  limiting the  pharmaceutical 
industry's  capacity  to export.  It will be  seen later that both France  and 
Italy practiceaprice restraint policy:  despite  this,  their exports  of 
pharmaceutical products  have  not  been at  a  disadvantage. 
32 It might  also be  asked  to what  extent  this  increase  in trade may  result 
from  the  partial internationalization of production,  with  the  firms  in each 
country  specializing in one  of  the major  categories  of pharmaceutical 
product. 
33 PART  II 
THE  POLICIES 
Definition  ----------
Pharmaceutical  products  available  in the market  can be divided  into  two 
categorie$  : 
(a)  proprietary medicinal products  :  according  to  the  EEC  definition  these 
are  medicines  prepared  in advance,  marketed  under  a  special  name  and 
packaged  in a  special presentation; 
(b)  generic  products  :  these  are  also medicines  prepared  in advance  and 
packaged  in a  special presentation but with  no  special  name,  thus 
differentiating  them  from  the proprietary products. 
In both  cases  the  pharmaceutical is characterized by  the  same  composition  of 
active  components,but  may  appear  in different pharmaceutical  forms  (tablets, 
suppositories,  injectable  aqueous  solutions, etc.). 
It is very difficult  to  ascertain  the precise  number  of  medicaments  availabl~ 
especially within  the  generic  category.  In  the  case  of proprietary medicinal 
products,  this  is easier  to establish and  the  table below,  relating  to 
1974-1975,  has  been drawn  up. 
Country  Registered  names  Pharmaceutical  forms 
Germany  26  000 
Belgium  7  300 
Denmark  1  698  3  400 
France  4  500  11  000 
Ireland  5  000  12  000 
Italy  8  932  16  150 
Luxembourg  5  742  8  654 
Netherlands  3  475 
United  Kingdom  29  741  ( 1) 
(1)  Including  lO.i439  in the  generic  category. 
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35 A.  THE  ORGANIZATION  OF  THE  PHARMACEUTICAL  MARKET  BY  THE  RELEVANT  AUTHORITIES 
1.  Introduction onto  the market 
In all countries  of  the  Community  there  are  laws  governing  the marketing  of 
proprietary pharmaceuticals.  Decisions  on whether  such  a  product  may  be 
marketed  are  taken  in Denmark  by  the  Registration Board  responsible  to  the 
National  Board  of  Health.  In  the  Netherlands  the  "College  for  the  judgment 
of  branded  or  packed  pharmaceuticals"  is  legally charged with  this 
responsibility.  In  the  other  countries  of  the  Community  it is  the Minister 
responsible  for  Health who  licenses  drugs  usually acting on  the  advice  of 
an  expert  committee. 
The  criteria applied  are  quality,  safety and  efficacy for  stated uses.  In 
Denmark,  Belgium,  Germany  and  France,  licences  are  given for  five  years,  but 
can be  renewed  and  usually  are  renewed  without  a  review.  In  the  other 
countries,  licences  continue  unless  they  are  revoked.  In Denmark,  the  Law 
of  1954  applied  only  to  "new  chemical  substances" but was  amended  in 1976 
to  apply  to all products.  Old  (pre-1954)  products  are  currently being 
reviewed.  Similarly,  in France  the  Law  of  1967  applies  to all products, 
though  the  licensing procedure  is occasionally simplified  for  old  products. 
In the  other  countries  of  the  Community  all old  products  were  given  licences 
on  request  when  the  Law  was  introduced.  The  Law  to  license  the  sale  of 
drugs  in Italy was  consolidated  in 1934  and  a  series of  circulars between 
1963  and  1973  strengthened  the criteria which were  applied.  In  the 
Netherlands  the  operative  Law  dates  from  1958.  In Belgium  the  system of 
authorization was  introduced  in 1962  and  confirmed  by  a  Law  of  1964.  The 
German  Law  was  passed  in 1971  and  amended  in 1978.  In Luxembourg  the  Law 
was  passed  in May  1956. 
In  the  United  Kingdom  the  Law  was  passed  in 1968  and  carne  into effect in 
1971,  but it was  preceded  by  a  Committee  on  the  Safety  of Medicines 
established by  agreement with  the  pharmaceutical  industry  from  1964  to 
review  the  evidence  on  new  drugs  and  offer  advice  on  their  toxicity.  The 
pharmaceutical  industry  agreed  to  submit  data on  new  drugs  and  accept  the 
committee's  advice.  In Eire  the  Law  dates  from  1974  but was  preceded  by 
an  agreement with  the  pharmaceutical industry similar  to that  in  the  United 
Kingdom  dating  from  1966.  Products  are  reviewed  by  the National Drugs 
Advisory  Board. 
Article  39  of  EEC  Directive  75/319  requires  Member  States  to  review  old 
products within fifteen years  from  the  date  of  the Directive  and  make  them 
conform  to  Community  requirements.  In Ireland  and  the  United  Kingdom,  it 
is hoped  to  complete  the  review by  1983. 
In  1976  the  main  Community  Directives  on  pharmaceuticals  could  be  summarized 
as  follows  : 
36 Directive  65/65/EEC 
This Directive,  which relates  to  proprietary medicinal products  : 
(i)  requires  products  to  be  authorized  by  a  competent  authority  of  a 
Member  State before  they  are marketed; 
(ii)  lays  down  the  requirements  to be  satisfied for  each product  authorized; 
(iii) establishes  the  conditions  for  suspension  and  revocation; 
(iv)  lays  down  requirements  for  the  labelling of  products. 
From  November  1976,  the  following  Community  Directives relating to 
proprietary medicinal products  came  into force  : 
Directive  75/319/EEC 
This Directives,  which  aims  to facilitate  authorizations  to market  products 
in more  than  one  Member  State 
(i)  establishes  a  Committee  for Proprietary Products  to give  opinions  on 
whether  particular products  comply with  the  requirements  of  Directive 
65/65/EEC; 
(ii)  lays down  procedures  to be  followed  for  a  product  to be  authorized  for 
marketing  in more  than  one  country; 
(iii)  requires manufacturers  and  importers  of  products  to be  subject  to 
authorizations  and  requires  such manufacturers  and  importers  to have 
at  their disposal qualified  persons with responsibilities  to secure 
and  certify that products manufactured  or  imported neet  the  quality 
standards  required. 
Directive  75/318/EEC 
This Directive  lays  down  uniform rules  for  tests  and  trials,  the  compilation 
of dossiers  and  the  examination  of  applications  for  authorizations  to 
market  products. 
2.  Economic  Controls 
The  first question was  not whether  pharmacists  had  a  monopoly  in the 
ownership  of  pharmaceutical firms,  but  concerned  the  control  and  manufacture 
of  pharmaceuticals.  In other words,  is  a  pharmacist  required  to be 
responsible  for  the  operations in pharmaceutical production and  supervise it 
from  a  technical  point  of  view  ? 
37 Only  Denmark  and  Ireland reply firmly  in the  negative;  in Germany  the 
neeative  response  was  qualified by  the  information that persons with 
appropriate university qualifications  in other fields  are  allowed  to manage 
pharmaceutical production.  In  the  Netherlands,  where  similarly no  monopoly 
exists,  the  Government  requires  overall production responsibility  to be  in 
the  hands  of  a  pharmacist;  he  can,  however,  be  replaced  by  a  specialized 
chemist with  the  approval  of  the  committee.  In  Italy technical management 
of  pharmaceutical production may  be  in the  hands  of pharmacists,  graduate 
chemists,  or  graduates in chemistry  and  pharmaceutical  technology. 
On  the  other  hand,  the  law  requires  the  presence  of  a  pharmacist  in 
pharmaceutical  laboratories  in Belgium,  Luxembourg  and  France.  In France  the 
law requires  that  all pharmaceutical undertakings  must  either be  owned  by  a 
pharmacist  or haveapharmacist  on  the  management  board  or board  of directors 
(in the  case  of  a  company).  In both  cases  the  pharmacist is personally 
responsible  for  the  applicationofregulations made  in the  interest of public 
health;  in  the  case  of  companies,  this is without prejudice  to  the  joint 
liability of  the  company. 
It appears  clearly from  the  replies  that  monopoly  is rare,  and  even  though 
the  presence  of  a  pharmacist  is often required,  this  is for  reasons  connected 
with  public health rather  than  economics. 
Since  November  1976,  the  problem has  been regulated  by Article  21  of 
Directive  75/319/EEC.  According  to  the  Directive  pharmaceutical products 
must  be  produced  under  the  supervision of  a  qualified  person whose  training 
meets  the  conditions  prescribed  in Article  23  of  the  aforementioned 
Directive. 
It follows  that  a  country  can  lay  down  that,  on  its territory,  this person 
must  be  a  pharmacist  where  the university  studies pursued  by  such  a  person 
meet  the  conditions prescribed  in  the  aforementioned Directive,  but  the  same 
country  cannot  refuse  the  import  of  pharmaceutical  specialities from 
countries within  the  Community  where  their manufacture  and  control  have 
been  supervised  by  a  non-pharmacist  whose  studies  had  likewise met  the 
conditions  prescribed  in Article  23  of  the Directive. 
On  obstacles  to  investments  by  firms  with headquarters  located  outside  the 
EEC  the  answer  from all countries was  No.  Some  countries  (Germany,  Italy, 
Ireland)  added  that  such  operations  must  comply with  general  regulations 
on  the  sale  or  establishment  of businesses  laid  down  by  national  legislation, 
but  this  is  of  course  a  principle which would  be  respected  everywhere.  In 
Ireland,  far  from  raising obstacles,  the  authorities  actively encourage 
foreign  investment  in their country;  this  applies  to  the manufacture  of 
pharmaceuticals  in the  same  way  as  to  any  other  form  of enterprise. 
In all  the  countries  the  same  procedure  is  followed  for marketing  products  of 
foreign  origin as  for  domestic  products.  In Germany  a  licence  granted  in 
another  country may  be  recognised  as  equivalent  to  a  German  licence.  This 
38 however  is  only  a  possibility and  not  automatically  the  case;  the  licence 
granted  in another  country will be  recognised  in Germany  only when  the 
controls  carried out  in the exporting country are  similar  to  those practised 
in Germany. 
France  is a  special  case,  in that  the  conditions  imposed  for  marketing 
authorization are  so strict that  they  amount  to  a  virtual ban  on  foreign 
imports  of  pharmaceuticals.  The  latter accounts  for  onlyJl  %of  the i 
market,  are  authorised  item by  item,  and  are distributed  in France  solely 
through  the  central pharmacy  of  the Assistance  Publique  (a legal entity 
embracing most  of  the  public hospitals  in the Paris  region).  However, 
imports  are  expected  to  expand  in the  coming years. 
For  authorised  imports  the  later  controls  are  carried  out  in conformity with 
Article 2i of Directive  75/319/EEC. 
There  are  two  possibilities  : 
- importation from  another  EEC  country  :  each  consignment  must  be 
accompanied  by  a  certificate of  conformity prepared  by  a  qualified person 
employed  by  the  manufacturer; 
- importation  from  a  third  country  :  each  consignment  imported  is subject  to 
full qualitative  and  quantitative  analysis  of  either  the main  constituant 
or  constituants,  and  this must  be  undertaken by  a  person recognised  as 
qualified  by  the  legislation of  one  of  the  EEC  countries. 
1.  Monopolies 
A distinction must  be  made  between monopoly  in  the  ownership  of  pharmacies 
and  monopoly  of  the  sale,  retail or  wholesale,  of  pharmaceuticals. 
As  far  as  ownership  is  concerned,  a  monopoly  exists  in three  countries  only: 
Luxembourg,  Denmark  and  Germany.  Another  distinction must  be  made  in the 
case  of  Luxembourg;  there,  pharmacists  have  a  monopoly  in pharmacies  set up 
before  1905.  Since  then,  the  State has  been  the  titular owner,  with  the 
pharmacist merely  owning  the  stock-in-trade  and  fixtures  and  fittings. 
Although  there  is  no  absolute monopoly  in France,  the  great majority  of 
dispensing  pharmacies  belong  to pharmacists,  except  for  those  attached  to 
public  and  private institutions where  patients  are  treated,  health  insurance 
funds  and  the  miners'  social  security  fund.  No  monopoly  exists  in Ireland 
or  the  United  Kingdom,  but wholesale business  can be  carried  out  only  by  a 
licenced wholesaler whose  facilities  and  standards  are  regularly  checked  by 
the  Department  of  Heal~h.  In Belgium  there  is no  legislation on  the  ownership 
of  dispensing pharmacies.  In Italy,  although  the  great majority of 
pharmacies  do  belong  to  pharmacists  (92.50%  in 1975),  they  do  not  have  a 
monopoly.  Under  the  law  of  8  March  1968,  companies  are  no  longer  permitted 
to  own  a  dispensing  pharmacy,  but  public  assistance  and  welfare  institutions 
and  cooperatives  complying with  legislation laid  down  are still allowed  to 
do  so. 
39 The  same  la\v  authorised  the  establishment  of  new  connnunal  pharmacies,  muni-
cipal pharmaceutical  undertakings  (5.5  %)  and  hospital  "dispensaries"  open 
to  the  public  (1.5  %),  which  together  represent  50%  of all new  pharmacies. 
As  far  as  the  sale  of medicines  is  concerned,  certain distinctions must  be 
made.  In all countries,  only dispensing pharmacies  can  supply  products 
available  only  on  medical  prescription. 
For  other  products,  which  can  be  purchased without prescription,  the 
situation varies. 
Monopoly  of  ownership  is  accompanied  in Luxembourg  and  Denmark  by  monopoly 
of  sales.  The  same  applies  in Germany,  except  that  a  few  products  may  be 
sold  other  than  in pharmacies  :  "medicines  included  exclusively  for 
purposes  other  than  the  elimination or  alleviation of  illnesses, pains, 
bodily injuries  or  pains  arising  from  illnesses"  (Article  44  AMG  new 
version).  There  is full monopoly  regarding  the  sale of medicines  in Italy, 
France  and  Belgium,  although  there  is no  monopoly  of  ownership.  In all 
three  countries  there  has  to be  a  pharmacist  on  the  premises,  whether  the 
owner  or  an  employee,  although  an  exception is made  in Italy for  pharmacies 
set up  by decision of  the  provincial medical  officer in zones  where  no 
pharmacy  existed.  These  "dispensaries" keep  stocks  of basic medicine  and 
first-aid material,  but  usually  come  under  the  responsibility of  the  owner 
of  the nearest  pharmacy;  when  this  is not  possible  the  commune,  through  the 
local medical  officer or  another member  of  the medical  profession,  acts  as 
manager. 
In  the  same  way,  a  few  doctors  in France known  as  "propharmaciens"  are 
allowed  to deliver medicines  in remote  areas  far  from  a  pharmacy. 
Belgium makes  the  same  concession.  In  some  small hospitals  a  person other 
than  a  pharmacist  is  allowed  to deliver drugs  from  the hospital  supply.  In 
Denmark  patientscanbuy medecines  not  only  from  one  of  the  323  pharmacies 
belonging  to pharmacists but also  from  other  sales points  (which  are 
numerous)  where  the presence  of  a  pharmacist is not  compulsory but  these 
sales points  are  placed  under  the  regional pharmacist.  On  the  other hand, 
there  is no  monopoly  on  sales  in the  United  Kingdom,  Ireland  and  the Nether-
lands.  For  example,  in the  United  Kingdom,  doctors  and  dentists  can sell or 
supply medicines,  e.g.,  in rural areas;  the  same  applies  to ordinary  shops, 
which  can  sell certain simple  drugs  for  human  or  animal  application.  In 
Ireland,  doctors  are  not  allowed  to sell pharmaceutical  products but  simple 
drugs  such  as  analgesics  may  be  sold  in supermarkets. 
The  absence  of  a  monopoly  does  not  imply  that other sales outlets  can sell 
all pharmaceutical products  freely.  For  drugs  which must  be  sold  only 
under  prescription,  the  presence  of  a  pharmacist is always  essential.  For 
off-prescription drugs,  where  there is no  pharmacist,  free  sale is usually 
restricted  to  relatively  simple  or  paramedical  products,  as  in Germany. 
A related question was  whether  pharmacies  were  allowed  to sell products  other 
than medicines,  and  if so,  whether  their freedom  to do  so was  total or 
limited·. 
40 An  affirmative  answer  was  received  from all countries.  Many  examples  were 
cited  :  they  ranged  from  articles of hygiene  to  cosmetics,  from  thermometers 
to  bandages  and  plasters,  from baby  foods  to health foods. 
This  type  of  sale  seems  to be quite  free  from  restriction~ except  in four 
cases.  In Germany,  legislation determines  the  conditions  of  sale for 
products  other  than medicines  (section 12  Apothekenbetriebsordnung).  In 
Italy,  pharmacies  must  have  a  licence  from  the  cotmnune  and  be  registered  at 
the  Chamber  of  Commerce  to sell products  other  than medicines.  This  applies 
to health products  for babies  or elderly people,  as  well  as  to products 
appearing  on  a  list drawn  up  in  agreement  with  the  trades  and  professions 
concerned,  under  the  patronage  of  the Ministry for  Industry  and  Commerce. 
In France,  pharmacists  can sell only merchandise  appearing  on  a  list 
established by  the Minister for  Public Health  on  the  recotmnendation  of  the 
national  council  of  the  Order  of  Pharmacists.  In Belgium,  it is forbidden 
to  sell other  items  but  law  allows  the  sale  of  accessories,  hygienic 
products  and  certain dietary foodstuffs. 
To  give  an  idea,  the  French report estimates  that  these  sales of non-
pharmaceutical  and  non-proprietary products  account  for  14  % of  the  turnover 
in pharmacists'  shops.  In Belgium this percentage  is between  4%  and  5  %. 
2.  Conditions  of  establishment 
The  first question was  whether  there  is  any  control  over  the  number  of retail 
pharmacies  and,  if so,  what  criteria are  used. 
Only  the  United  Kingdom  and  Ireland  have  no  limit of  any kind.  Whilst  in 
Germany  there  is no  limit  on  the  number  of pharmacies,  no  licenced pharmacist 
may  own  more  than  one.  In  the Netherlands  there is no  legally-imposed  limit, 
but  the  profession makes  its own  restrictions  :  a  cotmnittee  of  the 
Association of  Pharmacists  regulates  the  setting-up  of  pharmacies  and  in the 
big  towns,  this practically amounts  to  a  limit on  the  ratio. 
In all the  other  countries  the  number  of  pharmacies  is restricted either by 
legislation or  regulations.  The  criteria vary,  but are essentially based  on 
the population needing  to be  served,  with proportionally  fewer  pharmacies 
per  segment  of  the  population in  the  larger  towns.  Geographical  factors  may 
also  be  involved;  distances  to be  covered,  and distances between 
neighbouring pharmacies,  both come  into  the picture. 
Italian regulations  on  this matter  seem  to be  more  "interventionist" than 
others,  the  pharmacy being virtually regarded  as  a  public service  and 
benefiting  from  certain concessions.  Provision is made  for  every  commune  to 
keep  an up-to-date record,  revised  every  two  years,  showing  the  number  and 
location of  all pharmacies,  the radius which  they  serve  and  the  zone. 
41 In fact,  the  ratio between  the  number  of  pharmacies  and  the  population served 
varies  considerably.  The  table below gives  the  number  of stockists per 
million inhabitants,  excluding hospital pharmacies.  The  ratios  obtained vary 
by  a  factor  of  almost  1:8,  with Denmark  and  the Netherlands  at  one  extreme 
and  Belgium at  the  other, whilst  the  policy of  limiting the  number  of  outlets 
seems  to make  little difference,  since  Ireland  and  the  United  Kingdom,  in 
neither of which  a  limit is  imposed,  are  at widely varying points  on  the 
scale. 
Denmark  65 
Netherlands  66 
Luxembourg  191 
United  Kingdom  200 
Germany  220 
Italy  243 
France  356 
Ireland  380 
Belgium  527 
These  figures  are  averages,  and  the  ratio may  vary widely within  the  same 
country.  This  is particularly noticeable  in Italy, where  the  authorities 
have  tried  to encourage  the  setting up  of  pharmacies  in rural  and 
mountainous  areas,  where  per  capita  income  is  low  and  there  is not  enough 
incentive  to  private enterprise.  When  this happens,  the  authorities either 
directly encourage  the  creation of  communal  or hospital  "dispensaries"  or  act 
indirectly in granting subsidies  to private  pharmacies.  Under  the  present 
law  SO  % of  all new  pharmacies must  be  opened  by  the  communes  and  hospitals. 
As  far  as  the  opening  of  non  profit-making  pharmacies  is concerned 
(hospitals,  dispensaries,  pharmacies  operated  by  provident  funds  or  the 
social  security authorities),  regulations vary  from  one  country  to  another. 
There  are  no  pharmacies  run by  insurance  funds  or  cooperatives  in Luxembourg. 
In France  they  can be  authorized  only  by  the Minister  of Public Health.  This 
amounts  in practice  to  a  ban,  since  no  Minister  of Public Health has 
permitted  the  setting up  of  a  pharmacy  of  this kind  for  30  years.  The 
situation in Italy was  frozen  in  1968  as  regards  public assistance  and 
welfare  institutions  as well  as  cooperatives  :  these bodies  can  continue  to 
run  any  "dispensaries" which  existed when  the  law  \Jas  passed,  but  cannot 
transfer,  set up,  or  acquire  any  new  ones. 
In  Germany  the  authorized health insurance  funds  are not entitled  to  set  up 
their  own  pharmacies.  There  are  two  obstacles,  one  legal  and  one  financial, 
to  the  setting up  of  hospital  "dispensaries";  in small hospitals  they would 
not  be  profitable, whilst  the  law  forbids  several hospitals  to  run  a  joint 
pharmacy  unless  they  are  owned  by  the  same  body. 
In Belgium and  Ireland,  non  profit-making  organizations  and  private 
individuals  are  treated  in the  same  way  when  opening  a  new  pharmacy.  There 
is  no discrimination.  The  same  is  true  in  the  United  Kingdom  in  so  far  as 
there  is  no  limitation on  the  number  of  pharmacies. 
42 3.  Conditions  for  the  acquisition of  pharmacies 
There  are  no  special  regulations  governing  the  transfer  of businesses  in 
Ireland,  the United  Kingdom  or  Germany. 
Such  transactions may  also be  carried out quite  freely in Belgium,  except  as 
regards  one  consideration  :  the  maximum  price for.pharmacist's  shops  open 
to  the  public is set at  150  % of  the  gross  annual profit,  averaged  out  over 
the  preceding five  years. 
In Luxembourg,  as  already mentioned,  the  law makes  a  distinction between 
pharmacies  opened  before  1905  and  others.  In  the  former  case  the business 
may  be  transferred;  in the  latter it cannot,  since it belongs  to  the  State. 
In France  a  pharmacy may  be  acquired  in any  manner  involving valuable 
consideration  (purchase,  exchange)  or  otherwise  (gift,  legacy,  inheritance). 
The  new  proprietor  does  not  have  to  apply  for  a  new  licence.  He  retains 
the  licence  issued  to  the  pharmacy when  it was  first registered  or when  it 
was  opened.  However,  the  new  proprietor must  comply with  the  general rule 
relating  to  the acquisition of pharmacies  :  prior declaration to  the 
prefecture where it is  to be  registered.  Application for  registration,  made 
on  unstamped  paper,  is  appended  to  a  dossier  containing  the relevant 
supporting  documents  required  by  the  Code  of  Public Health. 
Freedom of  transfer is  the  most  restricted in Italy.  Communes  and  hospitals 
are  not  allowed  to  acquire  a  pharmacy,  but may  have  one  allotted  to  them 
which  has  become  vacant  or  was  newly  created  for  the  purpose.  Individual 
pharmacists  can  acquire  a  business  only after succeeding  in  a  provincial 
competition,  where  both their qualifications  and  their  examination results 
are  considered.  The  same  procedure  takes  place when  a  business  is  ceded 
through  the  death  of its owner;  pharmacies  cannot  be  inherited,  even when 
the heir is qualified.  In addition,  a  pharmacist  can sell or  otherwise 
transfer his business  only after five  years  and  cannot enter  the  competition 
for  a  new  pharmacy  for  at  least  ten years  from  the date  of  transfer  of  the 
old  one;  however,  he  is offered  one  opportunity  of  acquiring  a  second 
pharmacy  in  the  year  following  the  transfer without having  to resit the 
examination  (under  the  law  governing  trade  and  commercial  activities). 
43 B.  PRICING  POLICY 
1.  Production 
In  only  two  countries,  the Netherlands  and  Germany,  do  manufacturers  appear 
to have  complete  freedom  in fixing  their prices. 
In  the  Netherlands  the  market  and  competition offer  the  only  form  of 
restraint.  The  Dutch  report  indicates  that  this pressure has  been  enough 
to keep  prices  at  a  reasonable  level,  and  in some  cases  to bring  them down. 
In  Germany  the  pharmaceutical  industry is subject  to  scrutiny by  the 
antitrust authorities,  as it is in every  country.  The  Federal  trust office 
can force  a  price  reduction for  a  certain product if it can be  proved  that 
a  dominant  position in  the market  is being exploited  (Article  22  of  the  law 
against  the  prevention of unfair  competition). 
Ireland  and  Denmark  occupy  an  intermediate position on  this  question.  In 
Ireland  there  is no  regulation of  the prices  set by  the  industry for  new 
products.  On  the  other  hand  there  is  a  control  on  raising prices  of products 
already  on  the market.  Authorization for  a  price rise has  to be  given by  the 
Ministry  of  Industry  and  Commerce's "Price Commission".  It is granted  only 
in cases where  production or distribution costs  have  increased. 
In Denmark,  from  1954  to  1975,  the Minister  of  Health had  the  right  to 
determine  the  price of  specific drugs.  In practice,  the  right was  hardly 
ever  exercised,  and  registration of  drugs  proceeded  solely on  the  basis  of 
health  considerations. 
The  "Medicines  Act"  of  1975  was  intended,  when  it came  into force  on 
1  January  1976,to operate  a  real price control  system.  The  task was  given 
to  the monopolies  office  (Monopolies  Commission Agency  or MCA),  which was 
charged with  applying  the  same  regulations which were  in force  for  other 
sectors  of  industry  to  the  pharmaceutical  industry.  But  owing  to  the 
particular position of  the  pharmaceutical  industry,  the  MCA  was  requested 
by Parliament  to prepare  a  special report  on  the  type  of control  to be  used 
in this sector,  for  1  January  1978.  In  the  meantime,  the  MCA  tried  to  find 
ways  of  imposing  the  general price  control regulations  - which  attempt  to 
sanction  any  prices  considered  not  "reasonable" - on  the pharmaceutical 
industry.  It had  little success.  In  the  spring of  1976,  the  MCA  demanded 
a  reduction of  20%  in the price of  tranquillizers.  In May  1977,  the 
Monopolies  Tribunal  reversed  this decision,  on  an  appeal  by  the  industry. 
44 The  most  original  formula  seems  to be  that  implemented  in the  United  Kingdom. 
Laws  exist under  which  prices  could  be  controlled but  in practice  they  are 
controlled by  the  provisions made  on  agreements.  The  British Association of 
the  Pharmaceutical  Industry  and  the Ministry  of  Health have  worked  out  a 
joint programme  on  price regulation applicable to all firms  supplying drugs 
under  the  National  Health  Service  (NHS).  Excluding  the  small  firms  all 
companies  have  to  submit  for  each  financial  year  a  breakdown  of  their sales, 
costs  and  capital outlay  for  the production of  dr~gs.  The  Department  of 
Health  and  Social  Security  then determines whether  the  company  has  made  a 
reasonable profiton sales  of  pharmaceuticals  taking into account  its capital, 
research  and  investment.  If the Department  considers  too  much  profit has 
been made  it negotiates  an  overall reduction.  The  company  must  then  reduce 
the  prices  of its specialities in order  to achieve  the  overall reduction 
requested,  but it is usually free  to  decide which  prices  should be  reduced 
provided  the  overall reduction is obtained. 
The  Department  considers  that  the  procedure  has  kept prices  at  a  reasonable 
level for  the  NHS,  while  ensuring  a  viable  and  healthy industry essential  to 
the national  economy. 
In Belgium,  Italy,  France  and  Luxembourg  price control  in the  pharmaceutical 
sector has  been effected by  the provisions  in the  regulations.  In  Belgium 
price  control has  been  the  responsibility of  the Ministry of Economic 
Affairs  :  from  1953,  the price of  new  drugs  and  price  increases  for existing 
products were  subject  to ministerial authorization until 1975;the criteria 
varied  according  to whether  an  equivalent  of  the  drug  had  been developed 
abroad  or not.  When  the  equivalent  of  the  drug had  originated  abroad,  the 
price  of  the  product  on  sale in Belgium,  whether  imported  or manufactured  in 
the  country,  could  not  exceed  the  selling  price  to the  public in its 
country  of  origin. 
A system along similar lines was  applied  in Luxembourg. 
When  the  drug  had  no  equivalent  abroad,  the manufacturer's  prime  cost was 
marked  up  according  to  a  certain profit margin which varied inversely with 
the  cost of  raw materials  (120,  90  or  60  %).  But  to encourage  Belgian 
research programmes,  these  margins  were  increased  to  140,  110  and  80  % for 
the  first  five-year  period  of  sales of  a  new  product,  provided  that it 
represented  a  new  therapeutic  substance  and  was  the result of  research 
carried  out  in Belgium.  The  same  principles  guided  the  Luxembourg 
legislation. 
In  1975,  new  legislation was  passed.  This  permits  the Minister  for  Economic 
Affairs  to  determine  maximum  prices  for  specific drugs,  after consultations 
with  "a price  commission for  specific drugs"  (on which  consumers,  the 
industry- manufacturers,  importers  and  distributors,  - and  the various 
ministries  involved,  are all represented).  The  following  factors  are  now 
taken  into account  : 
- the  elements  which make  up  the manufacturer's  or  importer's price,  plus 
their turnover; 
-general economic  factors  (investment,  employment,  exports); 
45 - comparative  elements  :  international  (with  the  price  level  in other 
countries)  or  national  (with  the  established price of  similar drugs 
already in use). 
The  earlier  legislation had  its  pos~t~ve and  negative  aspects.  Positive  -
the  prices  of  products  already  on  the market  were  controlled,  at least  up 
until  1973  :  negative  - there was  little incentive  for  the  development  of 
Belgian processes  and  products,  as  profits were  proportional  to manufacturing 
costs.  The  system  of  fixing prices  for  imported  products  or for  those 
manufactured  in Belgium under  license  in accordance with  prices  in their 
country  of  origin had  the  effect  of  favouring  companies  in countries where 
prices were  high,  or  VAT  rates were  greater  than  in Belgium.  The  proof  that 
these  pricing arrangements  were  fairly  generous  was  afforded  by  the  case  of 
medicaments  which  were  eligible for  reimbursement  by  the  health  services  : 
often,  the  reimbursement  approved  by  health  insurance  organizations was  such 
that  firms  decided  to  cut  their prices voluntarily  to  levels  below  those 
accepted  by  the  Department  of  Economic Affairs. 
The  new  system set up  under  the  law  of  1975  seemed,  on  the 
be  more  effective.  This  was  mainly  achieved  by  comparing 
requested  by  manufacturers  either with  the price  of  other 
similar products,  or with  the price  in all other  countries 
country  of  origin),  after deduction of  VAT. 
other hand,  to 
the  price 
identical  or 
(not  only  the 
In Italy changes  in legislation were  introduced  in  1970,  but  did not  come 
into effect until  June  1977.  Under  the  earlier system  the Ministry  of 
Health,  assisted  by  a  committee  of  experts,  was  the  competent  authority for 
the  fixing  of  specific drug prices.  The  method  is fairly  simple  : 
calculation of  the  manufacturer's  prime  cost,  which  includes  the  cost  of 
medicinal  raw materials,  material  used  in production,  labour  costs  (direct 
and  indirect)  and  running  costs; 
multiplication of  the  prime  cost by  a  coefficient varying between  2.5  and 
4,  in inverse proportion  to  the  total cost of manufacture.  This multipli-
cation produces  the margin  for  covering general  and  distribution expenses. 
The  review of  registered  specific drug prices is  the responsibility of  an 
interministerial pricing committee which has  exercised its authority  on  more 
than  one  occasion. 
Under  the  new  system,  the  same  interministerial  pr~c~ng committee will be 
responsible  for  fixing  new  prices  and  revising old  ones. 
It will be  a  more  complex  system,  consisting of  : 
- breakdown between  costs  of  raw materials  and  materials  used  in production; 
-calculation of  conversion  costs  (cost of  labour,  industrial value  added); 
46 inclusion of  a  margin  over  and  above  the  previous  sums,  to  cover  costs 
of research,  advertising,  and  capital return; 
- profit margin plus  VAT. 
To  cushion  the  abrupt  changeover  to  the  new  pricing system for  specific 
drugs  which  are  already  on  the  market,  upward  price  adjustments  for  an  18-
month  period  are  limited  to  30  % and  downward  adjustments  to  20  %.  At  the 
end  of  this  period,  the  prices  calculated  on  the  new  basis will be  applied 
without  any  restrictions. 
A percentage  breakdown  of  the  selling price  to  the  public,  arrived at using 
the  system which  has  been  in force  up  till now,  is  as  follows 
industrial prime  cost 
administrative  costs 
general  costs 
publicity 
commercial  expenses 
returns  and  exchanges 
samples 
manufacturer's profit 
distribution costs 
33.33  % 
6.60  % 
1.66  % 
3.34  % 
3.34  % 
1.66  % 
7.52  % 
6.33  % 
36.00  % 
The  policy has  had  the effect of holding drug  prices  down  (the  average  cost 
has  increased much  less  than  the  general price  index).  But  a  bad  result has 
been  the  disappearance  of  some  cheap  patent medicines  of  the  older  type, 
which  nonetheless were  of  proven  therapeutic value,  in favour  of  new 
products,  some  of which  are merely  new  presentations  of  old  remedies.  It 
was  to  ameliorate  this  awkward  situation that  a  general  price rise of  12  % 
for all products  on  the market  before  28  February  1974  was  granted. 
When  the  new  law  g1v1ng  authority  to  the  interministerial pricing committee 
came  into effect  in 1977,  the  revision of all existing specific drugs  was 
undertaken  in  two  stages  (June  and  December). 
Finally,  in France,  the  price  of  specific drugs  (other  than  the patent 
medicines  on  sale  to  the  general public)  is  fixed  by  a  "committee  for  the 
admission  of  drugs  to  the  list of  products  which  are  reimbursable  by  the 
national health services" which was  set up  in June  1967  in its present  form, 
and  which meets  in  the Ministries  of  Public Health  and  Social  Security.  The 
same  procedure  is followed  whether  the  patent drug is  a  new  one  or  one  which 
has  been marketed  already at  a  different price.  The  committee  establishes 
for  each  : 
the manufacturer's  prime  cost  :  cost  of  components  and  packaging materials, 
labour  costs,  production  and  control  costs; 
- the manufacturer's  total  cost  :  the  prime  cost  to which is  added  commercial, 
administrative  and  financial  expenses,  taxes  and  research  expenses  (in 
France); 
- the  gross  production  cost before  taxation  the  manufacturer's  total cost 
to which  is  added  capital return  and  profit margin. 
47 However,  the  price which  is set  does  not  depend  only  on  these  simple  factors. 
The  committee  also  takes  into consideration  the  cost of  treatment  by  the 
drugs  of  similar  therapeutic value. 
Exactly  the  same  procedure  is followed  for  price  rev1s1ons  of  existing drugs. 
Increases  are  requested  by  the manufacturer,  and  do  not  generally exceed 
30  %.  Decreases  arise  when  a  new  drug which  is  cheaper,  but has  the  same 
properties,  is  introduced.  When  the basic active  component  becomes  cheaper, 
there  may  also be  a  price decrease.  Requests  for  price decreases  are 
followed  by  a  programme  extending  the  decrease  over  a  period  of  time,  on 
which  the manufacturer  is  consulted  (for  example,  a  programme  to  lower  the 
price  of  ampicillins by  30  % is in progress  at  the present moment,  and  will 
be  completed  by  1  January  1979). 
The  results  of  ten years  of  operating by  the  committee  seem  to  indicate  that 
it has  reintroduced  an  element  of  competition,  without  affecting the 
consumer,  and  has  set up  favourable  conditions  for  a  slow increase in prices, 
and  even  sometimes  price-lowering.  The  trend  in the retail price  index 
when  compared with  the  rise in the  cost  of medicaments,  shows  that  the 
latter have  risen less  than  the  overall  increase  for all products. 
In short,  very  great differences  exist  in  the various  countries'  approach  to 
the  question  of  control  of manufacturers'  prices  for  pharmaceutical products. 
It is interesting to note  that  the  four  countries which  introduced  a  system 
of price  control have  all had  to modify  them  in the  direction of  greater 
control  (France  in  1967,  Italy in  1970,  Denmark  and  Belgium in 1975).  The 
pragmatic  approach  adopted  by  the  British leaves  more  flexibility  to  changing 
situations. 
The  various  countries'  attitude  to price  control  seems  to depend  on whether 
the  authorities believe  in  the  effectiveness  of  competition between 
pharmaceutical manufacturers.  In  the Netherlands,  Ireland  and  Germany  the 
authorities believe  that competition will have  a  restraining effect  on 
pricing.  In the  United  Kingdom  they  do  not believe  that  competition has  the 
right effect  and  the  controls  are  intended  to  ensure  (among  other  things) 
that  no  excess  and  unjustified profits  are made  as  a  result of  a  monopolistic 
or  semi-monopolistic  situation. 
In France,  Italy,  Belgium  and  Denmark  the  authorities put  no  trust in 
"spontaneous"  competition,  and  try  to offset  the  absence  of  competition by 
checking prices  in the  context  of  the  firm,  and  also  in comparison with 
national  and  international prices.  This  does  not  exclude  the possibility 
of  controlling prices directly.  The  authorities may  decide  on  a  general 
price  freeze,  which  affects pharmaceutical products  like all others,  or  they 
may  simply  freeze  the  price  of  pharmaceuticals,  or  even raise  them  (as  they 
did  in Italy in 1974).  But  these  are  generally  temporary  and  short-lived; 
they mitigate against  a  true pricing policy,  whether it be  one  of  liberalism 
or  containment. 
Except  in  the  United  Kingdom  and  Italy,  in no  country  are  the  pharmaceutical 
laborqtories  authorized  to  return  any  discount  to health insurance 
organisations  (or NHS). 
48 In  the United  Kingdom  firms  are  asked  to  pay  to  the  National  Health  Service 
part of  their profits if they  are  higher  than was  expected  at  the  time  the 
prices were  fixed  to  leave  only  a  reasonable profit margin.  Between  1966 
and  1976 it occured  17  times.  Under  the  new  provisions  accepted  by  the 
industry in  1977,  estimated  financial  results will be  prepared  at  the 
beginning of  each year.  Repayments  are  expected  to be  fewer  in  the  future 
but  could still happen. 
In Italy repayments  were  made  but not  by  individual  firms  nor were  they 
related  to  "excess profit margins".  During  the  years  1955-1970 all 
pharmaceutical  firms  have  had  to  give  a  12  % discount  to health insurance 
organizations.  In October  1970  this was  raised  to  19  %.  The  overall nature 
of  this  obligation,  coupled with  the  fact  that  upward  price revisions  for 
old  products  were  not permitted,  represented  a  heavy  burden for  some  firms; 
discounts  were  not  given,  in some  cases,  for  months  and  even years.  This 
system was  discontinued  by Decree  No  187  of  4  May  1977,  in application of 
Law  No  395. 
On  the  second  point,  there  are  great  divergencies.  Advantages  for 
dispensing pharmacists,  other  than price discounts,are proscribed  in Belgium. 
In Denmark  they  can be  given only  to hospital "dispensaries".  In other 
countries  they  are not  legally prohibited;  they  can be made  as  cash  or 
quantity discounts,  which  in practice comes  to the  same  thing.  In  the  latter 
case,  extra quantities  are  supplied  free-of-charge.  This  happens  in  the 
Netherlands  and  Germany.  In  the  Netherlands  discounts  can  only  theoretically 
be  given  following  agreement between  the manufacturers'  professional 
organization  and  dispensaries.  However,  in practice, manufacturers  supply  a 
considerable quantity  of  free  products  to hospital dispensaries,  dispensing 
chemists  and wholesalers,  and  to  those  doctors  who  are  permitted  to sell 
drugs. 
Cash discounts,  that is  a  percentage  of  the  selling price,  are  offered in 
Ireland,  France,  United  Kingdom,  Belgium  and  Italy.  Usually rebates  depend 
on  the  size of  the order,  or  the  speed  of  payment which  can  give  rise  to  a 
discount.  Generally  speaking,  where  discounts  are  allowed  there  is no 
regulation governing  them,  and  it is up  to  the manufacturer  to decide what 
he wants.  The  only rule  in force  seems  to be  one  in France  concerning 
rebates  to wholesalers.  For  sales  to  these,  the  manufacturer  can  set up 
a  scale  of prices,  depending  on  the wholesalers'  overheads.  The 
administration must  be  informed  of  these  scales,  and  manufacturers  are ~ot 
allowed  to make  rebates  or offer  special conditions  other  than  those 
specified  in  th~ scales. 
In principle, manufacturers  are not  authorized  to  grant hidden discounts  to 
dispensing pharmacists but it is difficult to  control  these hidden benefits. 
In the Netherlands  a  dispensing  chemist may  not  legally accept  any  discount 
from his  supplier  and  if he  does  so  he  must  pass it on  to  the  customer.  But 
the  usual practice is  said  to  be  otherwise. 
49 Information  on  this point was  found  to be unsatisfactory when  the  comparison 
was  made.  The  figures  quoted  were  not  given  on  an  identical basis  and  their 
origin differed.  In  a  number  of  cases  they were  provided by  the 
manufacturer's  organizations  themselves.  The  financial  profitability of  this 
sector  that is assessed  from  the  percentage  of  profit obtained  is  given 
below  by way  of  information  only  and  it would  be  a  mistake  to  draw  any 
comparisons,  particularly since  in certain countries the profit margins  given 
are  the  extremes,  whereas  in others  they  are  an  average.  Similarly,  and 
for  the  same  reasons,  not  much  importance  should  be  attached  to  the 
percentages  for  advertising  and  research. 
Lastly,  the  size  and  number  of multinational pharmaceutical  companies 
distorts  the figures,  since profits may  be  shown  in  a  given  country  for  tax 
reasons  rather  than actual profitability. 
An  attempt  is made  to  compare  the data in  the  rough  table below using  the 
following  breakdown  : 
1.  administrative  costs 
2.  manufacture  (including  transport,  raw materials,  and  general expenses) 
3.  processing  and  packaging 
4.  research  and  development 
5.  patents  and  licenses 
6.  sales  promotion 
7.  profit 
1  2  3  4  5  6  7  Total 
Belgium  ---------- 50  - 80 -------------- 15  - 35  2  - 15  100 
Denmark  5  60  ---------- 10  5  10  10  100 
Germany  13.4  35.9 -------- 17  ---------- 23  10.7  100 
France  40-55-- 7  - 3  8  5  17  4  - 10  100 
Italy  5  --------- 60 --------- 8  3  20  4  100 
Netherlands  31  ------ 15  18  8  16  12  100 
United  Kingdom  11.5  ----49.2 ------- 12.1  1.7  13.7  11.5  100 
There  is no  breakdown  for  Ireland,  and  Luxembourg,  it may  be  remembered, 
has  no  pharmaceutical  industry. 
In most  countries  the  figures  are  for  the  total activities  of  pharmaceutical 
companies,  namely  all manufactured  products,  whether  sold  on  the  domestic 
market  or  exported. 
In  Denmark  and  the  United  Kingdom,  however,  the  figures  relate  only  to  the 
domestic market,  and  are  confined  to  products  on  prescription.  In  the 
United  Kingdom  the  figures  relate  to products  on  prescription provided  under 
the  NHS  and  manufactured  by  the  larger  companies.  The  data were  obtained 
from  different  sources  (the  administration in France  and  the  United  Kingdom, 
the  pharmaceuticals  industry in Belgium,  Denmark  and  Italy). 
50 2.  Imports 
In Part  I-C  the  size of  foreign  trade  in pharmaceuticals  was  described.  It 
therefore  seemed  of  interest to  find  out whether  imports were  controlled, 
either  on  a  general basis  or  according  to  geographical  origin  (non-EEC 
countries or  the rest of  the world). 
No  provisions  exist in Germany  or Denmark  or  in the Netherlands.  In France 
the  question does  not  arise  in the  case  of  specific drugs,  since  imports  are 
practically non-existent,  in view of  the  strict rules  governing marketing 
of  imports.  When  imports  are  permitted,  their price is controlled by  the 
same  regulations which  apply  to  indigenous  products. 
In Belgium  the  price  of  drugs  which  are  imported  ready  packaged  and  the 
price of  those which,  while  having been  developed  in  a  foreign  country,  are 
manufactured  and  packaged  in Belgium,  are both  fixed  in  the  same  way.  There 
is no difference,  therefore,  in the  regulations.  In Luxembourg  the  same 
rule  applies  and  the  price  free  of  VAT  of  pre-packed  imported  drugs  must 
not  exceed  that  - also  free  of  VAT  - which  is in force  in  the  country  of 
origin,  using official exchange  rates. 
In the  United  Kingdom  prices  of  imported  drugs  are  subject  to  the  procedure 
under  the  joint programme  on  price regulation in the  same  ways  as  products 
manufactured  in the  United  Kingdom.  Transfer prices  are  checked  to  ensure 
that  the  costs  taken  into account  are  reasonable  and  exclude  any distortion 
which  might  result  from  art  abnormal  increase in transfer  prices. 
Italy has  adopted  a  special  set of  regulations.  If  there  is already  an 
Italian drug  on  the market  which  is  similar  and  already registered,  then 
the  imported  drug will be  sold  at  the  same  price  as  the  Italien one.  If, 
on  the  other hand,  there  is no  corresponding Italian drug,  the  price will 
be  calculated  according  to  the  selling price  of  the  drug  in its country  of 
origin,  increased  by  the  amount  of  exchange  costs,  customs  duty  and  freight. 
There  are  no  regulations  concerning pharmaceutical products  that  affect 
those  from  outside  the  EEC  differently from  those  of  EEC  origin.  There  are 
differences  in  customs  duty  payable  on  the  two  categories,  but  these  apply 
to  all products,  not merely pharmaceuticals. 
Finally,  there  seems  to  be  no  deliberate pricing policy for  imported 
pharmaceutical products.  Luxembourg,  with no  industry of its own,  imports 
patent drugs  already  packaged.  France,  because  of  its regulations,  imports 
hardly  any.  The  other  countries  import  more  or  less  according  to  the 
intensity of  their  own  national  industry;  there does  not  appear  to be  any 
connection  between  the  volume  of  imports  and  regulations  controlling their 
price. 
51 3.  Distribution 
Wholesalers'  gross  profits,  (1)  worked  out  as  a  percentage  of  the retail 
selling price  of  the  drug,  all  taxes  included,  are  as  follows 
Italy 
Ireland 
France 
Denmark 
Belgium 
Netherlands 
Germany 
Luxembourg 
United  Kingdom 
6.4 
8.69 
7.12 
6.4 
8.35 
14 
9 
8.8 
7.4  to  9.2 
Only  Germany,  up  until  1977,  has  not  had  any  legislation regulating 
wholesalers'  profit margins.  Since  1978  a  bracket  of  12-21  %of  the 
manufacturer's  selling price has  been fixed  depending  on  the price  of  the 
product,  but  these  provisions  apply  only  to sales  to pharmacists' shops. 
In  Ireland  there is no  legislation.  Wholesalers'  profit margins  are  fixed 
through  agreements  between  the  trade  and  the Ministry  of Health,  but profit 
margins  cannot  be  changed  without  authorization from  the  Price Control 
Commission. 
Likewise,  in  the  United  Kingdom,  wholesalers'  profit margins  are not  fixed 
by  law.  A manufacturer  is at  liberty to use  the  services  of  a  wholesaler 
or not  :  if he  does  so  he  must  pay  them,which  he  does  by  selling the  product 
to  the  wholesaler  at  a  price between 82.5  % and  86 %of  the  price at which  the 
wholesaler will on-sell  the  product  to  the retailer.  The  Department  of 
Health does  not  intervene  in this process  except  in cases  where  the 
manufacturer  offers wholesalers  conditions  that  are much  more  profitable 
than  the margin  allowed. 
The  situation seems  to be  the  same  in the  Netherlands  and  Denmark.  In  the 
former,  profit margins  are  laid down  by  agreement within the  industry,  and 
in the  latter,  through  agreements  between manufacturers  and  wholesalers. 
In Italy  legislation does  not  specifically limit wholesalers'  profits, but 
restrictions result  from  the  minimum  guaranteed  to  pharmacists  (see  b) 
below),  and  from  agreements  made  between  the interested parties in the 
industry,  and  through  the Ministry of Health. 
(1)  Generally,  except in the  United  Kingdom  and  Ireland, wholesalers sell 
only  to  internal markets,  their profit margins  relate only  to  these 
sales. 
52 In Luxembourg,  France  and  Belgium margins  are  laid  down  by  the Ministry  of 
Economic Affairs.  In all three  countries  a  percentage  has  been  laid down, 
but  in Belgium a  quantitative platform is also  introduced  :  whatever  the 
price of  the product,  the wholesaler's profit may  not  be  more  than  BFR  73  per 
item. 
Profit margins  appear  to have  remained  steady between  1965  and  1975,  except 
in  two  countries where  they went  down  slightly  (from 6.95  % to 6.40  % in 
Italy).  Only  the  Italian report mentions  that  the  particularly  low 
wholesale  profit margin  in that  country,  due  to  the  very  compet1t1ve  market 
in pharmaceuticals,  has  caused  the  number  of wholesalers  to decline  during 
the  last ten years. 
b)  ~~!2i1~!~ (pharmacies) 
Here  again,  reports were  asked  to  indicate gross profit margins  as  a 
percentage  of  the  retail selling price  of  the drug,  all taxes  included. 
Italy 
Ireland 
France 
Denmark 
Belgium 
Netherlands 
Germany 
Luxembourg 
United  Kingdom 
24.33 
33.33 
33.44 
32 
31 
26.2-33.4 
34 
33.83 
25 
In all countries apart  from  the Netherlands profit margins  are  laid down  by 
the  authorities.  In  the  Netherlands  they  are  fixed  by  groups within the 
industry.  In  the  other  countries  the  permitted margin is determined  either 
by  the  Ministry of Public Health  or by  the Ministry  concerned with  the 
economy  (Price  Commission  in Ireland). 
The  systems  used  are  usually complicated.  In addition to variations in the 
basic rate, extra honoraria depending  on  the  requirements  of  the patient,  or 
special problems  connected with  the  nature  or  the preparation of the medicine, 
may  also be  demanded. 
For  the  basic profit margin  allowed  on  pharmaceutical products,  only  Italy 
has  fixed  a  minimum  (25  %),  but  not  a  maximum.  France,  Luxembourg,  Italy, 
Belgium  and  Ireland  impose  the  same  profit margin  limit  on  all products 
irrespective of price.  In Belgium,  however,  there is  a  double  restriction 
the  margin may  not exceed  31  % of  the retai  1  price·. and  in absolute  value 
BFR  250.  In Germany  and  the Netherlands  there  is  a  decreas~ng sliding scale. 
In Germany  it ranges  from  68-30  % of  the  cost price,  but is no  more  than 
hypothetical,  as  it can be  increased  by  the quantity  disco~nts which whole-
salers give,  or decreased  by  the  discounts which  the pharmacists  grant  to 
health insurance  funds. 
In  the  Netherlands  the percentage profit  on  the retail price  for  products 
which  are U.A.  (the official price fixed  for  the health service)  ranges  from 
26.2  to  33.4  %. 
53 In  the  United  Kingdom  each pharmacist's profit margin varies  depending  on 
trade  (speed  of  turnover,  number  of  specific drugs  in stock,  depending  on  the 
prescription habits  of  local practitioners  and  the  local  sickness ratio). 
The  amount  received  by  the  pharmacist  for  prescriptions dispensed  under  the 
NHS  is calculated each month  on  the basis  of  four  factors 
- the wholesale  price  of  medicines  and  appliances  as  laid  down  by  the 
regulations  governing  the price of  pharmaceutical products,  less  a 
discount  of  0.1  % if the  chemist  dispenses  over  1  500 prescriptions  a 
month,  rising to  2.7% where  the  number  of prescriptions dispensed  is over 
8  000;  this tariff is  laid  down  by  the  Government  after consultation with 
the representatives  of  dispensing pharmacists; 
packaging costs  at  the  rate  of  2  1/2  pence  per prescription; 
- an  average  fee  of  24  1/2  pence  per prescription that varies with  the  type 
of  prescription in accordance with  the  scale fixed  for  pharmaceutical 
products,  and  depending  on  the  service  rendered  (for  exemple,  fees  for  an 
emergency); 
- an  allowance  equal  to  10.5  % of  the wholesale  price  of  the  drugs  and 
appliances  sold before deduction of  the  above-mentioned  discount  of 0.1 
to  2.7  %. 
Under  this  system,  the  last  two  factors  represent  the  pharmacist's  gross 
profit.  To  arrive at  the particular values  used,  the parties  involved,  i.e., 
the  Department  of Health  and  Social  Security  and  the professional body  of 
the  pharmacists,  make  regular  surveys  to establish the real cost  of  the 
work  performed  and  the  general  running costs,  as well  as  a  "net profit per 
prescription",  which  is negotiable.  The  process  is  a  contractual 
arrangement,  with  prov~s~ons for  periodical adjustments,  so  that  the 
objectives  of  the  scheme  can  be  achieved. 
Although  made-up  medicines  represent  a  very  small  part  of  the  total 
expenditure  on  pharmaceuticals  in most  countries,  it is noted  that  the 
pharmacist's  honorarium for  these  products  is determined  in various  ways. 
In Luxembourg  and  Italy  the Ministry  of  Public Health  lays  down  "preparation 
fees",  which  are  added  to  the  cost  of  the  raw materials  and packaging.  In 
Belgium  these  same  honoraria  are  fixed  by  agreement  between  professional 
bodies  representing  the  pharmacists  and  health insurance organizations.  In 
the  Netherlands  the  health  insurance  organizations fix  the  sum  which  shall 
be  reimbursed  in  the  case  of  made-up  medicines.  In  the  United  Kingdom 
preparationfees  are  fixed  by  the  Government. 
To  the  basic  honorarium for  making  up  a  prescription various  other  items 
are  sometimes  added.  Three  systems  of  remuneration exist  in other  countries. 
The  first  case  concerns  extra fees  which  are  not  linked  to  any  particular 
service  in  the  Netherlands,  where  the health  insurance  institutions pay  the 
pharmacists  a  fixed  annual  amount  of  HFL  21  000  for  the  first  5  000 
patients,  a  fixed  annual  amount  per  patient  (HFL  15.20)  and  an  additional 
amount  of  HFL  1.84 per  prescription. 
54 In  Ireland  the  system is  the  same  for patients who  are  not  covered  by 
general medical  services  :  in addition  to  the retail price which  includes 
a  margin  of  33  1/3  %,  chemists  receive  SO  pence  per prescription. 
The  second  case  arises if  the  pharmacist  is  called  on  to  perform extra work. 
The  most  frequent  case is  the  fee  for delivering medicines  outside  normal 
working  hours  (after  closing  time,  on  Sundays  and  public holidays);  this 
is paid  in Italy,  Belgium,  France,  United  Kingdom~  Luxembourg,  Denmark  and 
Germany.  In France  and  Italy provision is also made  for  special fees  for 
dispensing dangerous  or  toxic drugs  which  have  to be  entered  in special 
registers. 
In  the  third  case,  special payment  is received by  pharmacists  on  account 
of  the  need  to  provide all areas  of  a  country with pharmacists'  facilities. 
This may  be difficult in sparsely populated  or  poor  regions.  Two  ways 
exist  of  providing facilities when  the  number  of patients  - and  hence  the 
turnover  - is  small.  The  authorities may  decide either to  set  a  reasonably 
high profit margin,  which will  allow  a  small  isolated  pharmacy  to  survive, 
but which may  produce  excess  profits for  one  in  an  urban  area with  a  large 
or  growing  clientele,  or  they  may  decide  to set  the profit margin  at  a 
lower  level,  and  grant  extra remuneration  to assist  pharmacies with  a  small 
turnover.  This  system is practised  in  the  United  Kingdom.  In  some  cases 
pharmacists who  handle  only  a  limited  number  of  prescriptions,  but who  are 
considered  to provide  a  necessary  service  to  the  public,  receive  a  special 
grant  each year.  In  other  cases,  in Scotland,  the  rate  at which  the 
allowance  is calculated,  normally  10.5  % of  the wholesale  price,  increases 
progressively  for  pharmacies  handling  less  than  1  000  prescriptions  per 
month. 
Similar provisions  are  in  force  in  Italy and  Denmark.  In  Italy the  public 
authorities  subsidize  rural pharmacists whose  turnover  is  inadequate.  At 
present  2  800  pharmacists  are  subsidized.  The  subsidies  depend  on  the 
number  of  inhabitants,  under  3  000,  and  the  receipts;  but  the  amount  of 
aid  granted  is not  enough  to  encourage  the  opening of  new  pharmacies  in  the 
poorest areas.  The  Danish  system is more  ingenious  since it results  in 
some  redistribution between  pharmacists.  The  pharmacists  pay  an  amount 
between  3  and  9  % of  a  fixed  turnover.  When  their  turnover  exceeds  the 
average  turnover  by  a  certain percentage  they  pay  40  % of  the  difference. 
On  the  other hand,  some  pharmacies with  a  low  turnover  receive  a  subsidy. 
Retailers'  profit margins  laid  down  by  regulations  can be  cut  down  if they 
are  required  to make  repayments  to health insurance  bodies  or  the  NHS. 
(Repayment  of  excess  profits by wholesalers  is not  obligatory in  any  of  the 
Member  States). 
The  United  Kingdom  system  is basro  on  an  attempt  to arrive  at  a  balance 
between  payments  due  and  payments  made.  The  public authorities  do  not 
regularly review  the net  profit  due  per prescription  (in other word, 
remunaration  of  capital used,  which  has  remained  unchanged  at  16  % since 
1970).  They  achieve  the desired balance  by  adjusting fees  and/or  the  rate 
of  compensation;  net  profit is not  paid  separately but  is  included  in  the 
fees  and  the  compensation. 
55 In  other  countries  the  rebate  is  fixed  by  regulation.  This  is  the  case  in 
Germany  and  Italy.  In  the  former  country  the  statutory sickness  insurance 
pays  the  dispensing pharmacist  the  sale  price  of  the  drug  after deduction  of 
a  7% rebate  imposed  by  law  (lowered  to 5%  since  1978). 
In Italy health  insurance  institutions receive  a  16  % refund  on  galenical 
preparations  for all pharmacists.  In addition,  only rural  subsidized 
pharmacists  must  make  an  additional  5  %discount  on  specific drugs  and 
21  % on  prepacked  natural products. 
In  France  dispensing pharmacists  signed  an  agreement with  the  national health 
insurance  scheme  in  1968  to  refund  to  them  2.5  % of  the  total of  their sales 
to health  insurance patients.  The  system functioned  only  for  a  year  and  was 
replaced  in July  1970  by  one with  a  lower  basic rate.  Today  all that exists 
is a  convention  signed  by  friendly  society dispensaries,  guaranteeing  a 
refund  of  3  % to  the  health insurance  funds. 
The  reason  for  these  repayments,  however,  is not excess profits,  since  the 
provisions  extend  to all pharmacists,  whatever  their  turnover  or  net  income. 
For  example,  in Italy,  even pharmacies  in  the  country which  receive  a 
subsidy  are  obliged  to make  these  repayments.  As  prices  have  been more  or 
less  frozen  for  the past decade,  with profits held  at  a  low  level,  the  burden 
of  paying  back  refunds  to  the  health  insurance  funds  has  become  heavier. 
Under  the  special  system in force  in Luxembourg  dispensing pharmacists  allow 
a  discount  of  3.4  % to beneficiaries under  the worker's  insurance  scheme. 
To  sum  up,  the  structure  of  dispensing pharmacists'  earnings  is relatively 
rigid,  being  determined  either by  the percentage  of  the  price  of  products  or 
an  overall  contractual  remuneration  as  in  the  United  Kingdom.  It is equally 
rigid over  time.  The  changes  made  between  1965-1975  were  minimal  and  limited 
to certain countries  (Germany,  France,  Italy).  Consequently  they have  had 
little effect  on  the  overall  cost of  drug  consumption.  In  any  case  in all 
countries  the  system of  remuneration means  that  there  is almost  no 
competition as  far  as  the price  of  pharmaceuticals  offered  to patients or 
health insurance  organizations  is concerned. 
4.  Taxation 
The  figures  relating to  the  tax burden in each  country at the beginning  and 
the  end  of  the  period  1966-1975  were  given  on  page  8  of  Chapter  I. 
Depending  on  the  country  the  figure  given is either that  for  tax  on  turnover 
or  for  value  added  tax.  There has  recently been  a  tendancy  for  there  to be 
a  reconciliation between  the  different national policies.  Five  countries 
which  formerly  did  not  subject pharmaceutical products  to indirect  taxation 
do  so  today  and,  in 1975,  such  taxation existed in all the  countries. 
56 Taken  overall,  taxation  levied  on  pharmaceutical products  is relatively 
small.  The  only exception used  to  be  France,  where  until  1  July  1975,  the 
taxation  in force  amounted  to  17.6% instead  of  the  6.54%  to which it has 
since been  lowered.  It is doubtless  owing  to  the  fact  that  the  cost of  drug 
consumption  is  largely  supported by  some  form  of  group  insurance  (health 
insurance  schemes  or  national health services)  that  this is so. 
This  is  almost  non-existent.  In France  a  local  tax of  2.75  %on  the  selling 
price was  in force until  1967,  when  it was  abolished.  The  only exception 
seems  to  be  Ireland, where wholesalers  are  obliged  to  pay  a  tax on  the 
increased value of  their stocks;  curiously,  the  same  rule does  not  apply  to 
manufacturers  themselves. 
57 C.  THE  REGULATION  OF  CONSUMPTION 
1.  The  Doctor 
In all countries  in the  Community,  the  pharmaceuticals which may  be  paid  for 
in whole  or part by  health insurance  schemes  or health  services  are defined. 
In  Belgium,  Denmark,  Italy and  Luxembourg  special,  more  detailed  lists are 
maintained which  specify  those  products  which  are  covered  by health 
insurance.  In Germany  a  list is being prepared  of minor  drugs  which  are 
generally  consumed  in cases  of  light restriction of  physical well-being 
which will not,  or  only  under  special  conditions,  be  prescribed  under health 
insurance.  In France  and  the  Netherlands  a  list is maintained  of what 
doctors  are  recommended  to prescribe  under  health  insurance.  In  Germany  a 
special  list is  also being prepared  taking  account  of  cost  and  efficacy  to 
guide  doctors  prescribing under  health  insurance.  The  coverage  of  all  these 
special  lists varies  considerably in content  and  presentation. 
In  seven  of  the  nine  countries,  action is being  taken  to  influence  or 
regulate  the prescribing patterns  of  doctors  in  an  attempt  to  contain costs. 
The  two  exceptions  are  Belgium  and  France.  In  Belgium no  action is  taken  at 
all,  though  strong  sanctions  including prison  sentences  can be  imposed  on 
doctors  who  wrongly prescribe narcotic or  habit-forming drugs.  An 
administrative medical  committee  carries  out  checks  on  such prescriptions. 
While  no  action was  being  taken  in France  at  the  time  of  the  study,  a 
profile  of  doctors'  prescribing patterns is being prepared  for  the  first 
time.  Any  sanctions  against excessive prescribing would  have  to be  applied 
by  committees  representing all parties  to health  insurance  at  the  local  level 
where  payments  are  made. 
In  the  seven  countries  where  action is  taken it forms  part  of  the 
administration  of  health  insurance  (or  in  the  case  of  the  United  Kingdom  of 
the  National  Health  Service).  In Denmark  the  health insurance  agencies 
make  spot  checks  on  prescriptions.  Participating doctors  can in theory be 
fined  for  excessive  or  unnecessary prescribing,  but  fines  are,in practice, 
hardly  ever  applied.  In  Ireland  the  prescribing rates  of  doctors partici-
pating  in  the  General Medical  Services  covering  37  1/2  per  cent  of  the 
population are  analysed  annually,  and  doctors with high  rates  of  prescribing 
are  interviewed.  This  procedure  is believed  to be  effective.  No  legal 
sanctions backed  up  this  procedure  until  1978.  In  Luxembourg  consulting 
doctors  and  pharmacists  employed  by health  insurance  check  payments  for 
prescriptions.  The  consulting doctor  can make  a  formal  protest  to  any 
doctor who  issued  a  prescription arguing  that  it goes  beyond  the  limits  of 
what  is necessary  and  thus  breaches  the Health  Insurance  Code.  It is  also 
possible  for  him  to report  the  doctor  to  a  committee  set  up  under  the  Law 
by  the Minister  of  Health which  can  issue  warnings  with  the  ultimate 
sanction  of  banning  the  doctor  from  medical  practice. 
58 In  the  Netherlands  the  Council  of  sickness  insurance  funds  employs 
inspectors who  try to persuade doctors  to replace  expensive  medicines  by 
cheaper  ones  of  the  same  quality.  The  purpose  is  to  convince  doctors  to 
follow  the  recommendations  set  out  in "Regeling en Klapper".  This  provides 
the  inspectors with criteria by which  to  assess unduly  expensive  prescribing. 
In both  Germany  and  the  United  Kingdom  the  average, prescribing cost  of  each 
general practitioner is calculated  and  compared  with  that  of  the  average 
for  doctors  practicing in  the  area.  In Germany  the  system also extends  to 
each  type  of  specialist.  The  doctor who  exceeds  the  average  by  20-:30  % 
in Germany  is  informed  of  the  fact  and  asked  to explain what  appears 
at first sight  to  be  excessive  prescribing.  The  control is operated  by  the 
Association of  Panel  Doctors.  If a  doctor  continues  to  ~ver-prescribe 
without  a  satisfactory explanation he  can be  fined  by  the  sick board.  In 
the  case  of· persistent infringement his  panel  licence  can be  withdrawn. 
In England  and  Wales  the  control is  operated  by  salaried medical  officers 
(Regional Medical  Officers)  employed  by  the  Department  of Health  and  Social 
Security which  is  responsible  for  the National  Health  Service.  These 
doctors visit general practitioners whose  prescribing cost per patient  on 
his  list is  significantly  above  the  average  of  other doctors  in the  same 
area and  discuss  their prescribing with  them  and  offer advice.  They  might 
also  take with  them detailed  analyses  of  the  doctor's prescribing pattern 
and particular prescriptions written by  that  doctor which  seemed  at first 
sight  to  require explanation.  The  Regional  Medical  Officer reports  to  the 
Headquarters  of  the  Department  on  the  advice  given  to  the  doctor.  If,  in  a 
subsequent  analysis  of  the  doctor's  prescribing,  it appears  that  the  advice 
has  not  been  taken  this  can  lead  to  the  opinion  of  the  Local Medical 
Committee  being  sought.  These  Committees,  elected by all the  general 
practitioners  in  the  area,  can  recommend  that  a  proportion  of  the  doctor's 
remuneration is withheld.  It has  not,  however,  been necessary  to  take  a 
case  to  the Local Medical  Committee  during  the  past  four  years.  The  Regional 
Medical  Officer himself  is not  involved  in  any  disciplinary procedures;  his 
role is  to  act  as  adviser  to  the  doctor  in many  fields  including prescribing. 
In Italy what  a  doctor  can prescribe under  the health  insurance  schemes  is 
laid down  in the Health  Care  Handbook  which  contains  a  list of proprietary 
medicines  compiled  and  brought  up  to date  periodically  (new  products  being 
added  and  obsolete entries eliminated)  by  the Ministry of Health,  through 
an  appropriate  committee.  The  rules  for  the  use  of  the Health  Care  Handbook 
and  the  agreements  between  the  insurers  and  the  various health  authorities 
also determine  the  quantities which may  be  prescribed  and  dispensed. 
Doctors  and  pharmacists  are  bound  to  apply  these  prov1s1ons;  any 
prescriptions which  do  not  conform  are dispensed  entirely at  the patient's 
expense. 
The  various  Italian health insurance bodies,  until  they  are  replaced by 
the  National  Health  Service,  as  provided  for  under  the health  service  reform 
measures  (already partially in force  in respect  of hospital  treatment), 
exercise  control  over doctors'  activities  through  their  local  offices by 
checking prescriptions,bills  and  visits to patients.  Those  doctors  whose 
performance  is  open  to criticism are  called  in  to be  interviewed  (summoned  by 
letter)  and  finally,  in cases where  these  efforts prove  useless,  referred 
to  appropriate  committees.  The  INAM,  for  example,  has  a  committee  in every 
59 province,  chaired  by  the  president  of  the Medical Association  and  made  up  of 
six doctors  representing  the Ministries  of  Labour  and  of  Health,  the  INAM, 
the  employers,  the workers  and  the medical  profession.  At  INAM's  request, 
the  Commission  examines  the  case  referred  to it and  can  take  the  following 
steps  :  discharge,  formal warning,  suspension  from  practice  for  up  to  two 
years  or  permanently.  The  steps  taken concern only  the  relations  between 
the  doctor  and  INAM  and  in no  case  affect  the  former's  private practice, 
since  steps  concerning  the  latter can be  taken by  only  the  Council  of  the 
Medical  Association.  The  doctor  can  appeal  against  the  Provincial 
Committee's  decision  to  an  appropriate Central Committee. 
Sales  Promotion 
a)  Written Matter  Sent  to Doctors 
In France  and  the  Netherlands  all advertising material  sent  to doctors  has 
to be  approved  in advance.  In France drug  advertising is controlled by  the 
"Conrrnission  for  the  control  of pharmaceutical  advertising".  The  Commission 
ensures  that  any  advertising will neither endanger  nor  put  at risk public 
health,  that it is honest,  truthful  and  susceptible  of  proof  and  that 
possible undesirable effects  are  included.  Advertising certificates are 
issued  for  a  period  of  five  years.  In  the  Netherlands  an  office indirectly 
under  the  control  of  government  (KOAGG)  approves  all advertisements  before 
publication. 
In Ireland  sales  promotion  conditions  are  imposed  as  part  of  the  licensing 
of  products  by  the  Department  of  Health acting  on  the  advice  of  the National 
Drugs  Advisory  Board.  When  it is considered  that  a  risk is being created by 
the manner  of  promoting  a  product already  on  the market,  the  National Drugs 
Advisory  Board  takes  the matter  up  with  the  industry  and  generally achieves 
its objective.  In addition,  the  industry operates  a  voluntary  code  of 
marketing practice.  A special  committee  set  up  by  the  industry with a 
legally qualified  chairman,  who  is also  a  pharmacist,  adjudicates  on 
complaints that  the  code  has  been broken.  The  Committee  has  a  consultant 
medical  adviser  to  assist in such  assessments. 
In Italy  the  "labels"  (and  accompanying  illustrated brochures)  of 
proprietary medicines  have  to be  approved  by  the Ministry of Health at 
time  of registration of when  subsequent  amendments  make  this necessary.  All 
data sheets,  leaflets,  advertisements  and  particulars  given  to 
representativeshave  to  be  consistent with what  has  been approved-
particularly directions  for use,  warnings  and  contra-indications.  Graphic 
designs which  are  irrelevant, not of  a  scientific nature,  or which  can  give 
a  false  impression of  the  medicine  are not permitted. 
In Belgium regulations  specify that all advertising material or  technical 
and  scientific information relating to  a  particular product must  be  honest, 
truthful  and  susceptible  to proof.  It must  be  strictly consistent with  the 
details  submitted  at  the  time  of  applying for  registration of  the  product. 
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profession  and  pharmacists  must  include all  the  particulars  contained  in  the 
instructions  for  use  :  the  brand  name,  the  common  name,  the  name  and  address 
of  the  commercial  agent,  the  ingredients,  forms  of  packaging available,  dose 
and  method  of  administration,  therapeutic indications,  contra-indications 
and  side effects  as  established  at  the  time  of registration and,  if necessar~ 
an endorsement  required  by  the  public health department.  However,  this 
obligation does  not  apply  to  reminder advertising in which  the  brand  name  is 
mentioned. 
In Denmark  the  Law  requires all advertisements  to be  sober  and  factual  and 
not  to  give  an  exaggerated,  incomplete,  misleading  or deceptive  picture  of 
the medical  product.  Advertisements  sent  to doctors  are  submitted  to  spot 
checks.  In dubious  cases  the  industry's  own  ethical advertising board  or 
the  Health Department  can be  consulted  and  will  intervene  of its own  accord. 
In Germany  a  law  passed  in 1965  specifies  that misleading  advertising and 
vague  references  to reports,  testimonials  and  scientific publications  are 
prohibited.  An  amended  law  coming  into effect  from  1978  requires 
advertising material  or  advertisements  in medical  journals  to  contain the 
following  information  :  the name  and  place  of business  of  the  firm,  the  name 
of  the product,  the  composition including active  ingredients,  its field  of 
application,  contra-indications,  side effects  and  particular warning  signs. 
No  public agency  continuously monitors  the  observance  of  the  law but  legal 
proceedings  are  taken when  complaints  of  a  breach of  the  law  are made.  The 
Industry has,  however,  to prevent  advertisements which  give  prominence  to 
the  positive  features  of  a  product  and  much  less  prominence  to contra-
indications  and  side-effects.  Information  on  the  price is required  to be 
included  in advertisements. 
In Luxembourg,  regulations  published  in 1975  specify  that advertisements 
must  contain  the  name  and  the  address  of  the manufacturer  or product  licence-
holder,  the  name  of  the product  and  its active  components,  principal 
therapeutic indications,  contra-indications  and  side-effects,  dose  and 
method  of administration.  Abbreviated  advertisements  are,  however,  permitted 
containing only  the  name  of  the  product  and  the  name  and  address  of  the 
manufacturer  or  licence-holder. 
In the United  Kingdom  the Medicines  Act  1968  forbids  advertisements  to 
describe falsely  a  product  or be  likely to mislead  as  to its nature, 
quality,  uses  or effects.  It is also an  offence  to  recommend  the  product 
for  uses  other  than  those  stated on  the  product  licence  and  advertisements 
have  to be consistent with  the  particulars  on  the  product  licence. 
Regulations,  which  came  into effect in 1978,  specify that certain 
advertisements must  contain specific information on  active  ingredients, 
indications  for  use,  dosage,  major  side effects,  precautions,  contra-
indications  and  cost.  They  also  specify  the  prominence  to be  given to 
certain parts  of  the information,  prohibit misleading graphs  and  tables  and 
prohibit  the misuse  of words  like  "safe".  Further  controls  on  advertising 
practice are  implemented  by  a  Code  of Practice operated by  the  industry. 
The  Code  of Practice is  administered by  a  Committee,  which  includes 
independent members.  All  advertisements  have  to be  certified as  satisfactory 
by  at  least one  doctor  nominated  by  the manufacturing  company.  The  industry 
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compliance.  The  Code  of Practice  committee  has  agreed  to ensure  that  any 
advertisement  complained  of  by  the  Department  of Health  and  Social  Security 
will be withdrawn  pending  an  investigation by  the  Committee. 
b)  Restrictions  on  Representatives who  visit doctors 
Only  in Germany  and  the  United  Kingdom  are  there  laws  governing  the 
representatives  of  firms.  The  new  law  in Germany  coming  into effect in 
1978  specifies  that  representatives must  have particular specialist 
knowledge.  They  can be  prosecuted  under  the  law  following  a  complaint but 
no monitoring  of  their activities is planned.  Beyond  this,  there  is  no 
restriction on  what  they  can  say  to doctors.  In  Ireland  the activities  of 
representatives  are  governed  by  the  Industry's voluntary  code  of practice. 
In  the Netherlands  doctors  tend  to  limit  the  number  of visits  from 
representatives.  In Italy there  is  a  ministerial circular recommending 
the  qualifications which medical  representatives  should  possess,  how  many  of 
them  there  should  be  and  how  often  they  should visit doctors.  In  the United 
Kingdom  false  and  misleading representations  and  oral  recommendations  of  a 
product  for  uses  other  than  those  stated  on  the  licence  are  forbidden. 
When  a  sales representative visits a  doctor  and  initiates discussion of  a 
product,  he  places  a  copy  of  the data sheet  for  that product  (approved  by 
the  licensing authority)  before  the doctor.  The  Code  of Practice  of  the 
Industry  requires  representatives  to be  thoroughly  trained  and  maintain  a 
high  standard  of ethical  conduct. 
c)  Restrictions  on  Hospitality provided  to doctors 
In  Belgium  and  the Netherlands  there  are  no  restrictions.  In  Denmark, 
Germany,  Ireland  and  the United  Kingdom  hospitality is restricted by  the 
Code  of  Practice laid  down  by  the  Industry  or  by  agreement  among  firms.  In 
Germany  the  guidelines  laid  down  by  the  Industry  specify  that expenditure 
on  an  individual  participant  should  not  exceed  DM  30-40.  In  Ireland  and  the 
United  Kingdom  the  voluntary  code  states  that hospitality must  be  modest  in 
nature  and  cost.  In  the  United  Kingdom  an  agreement  reached with  the 
Industry in  1977  specifies  that hospitality can be  allowed  only  as  a  charge 
on  the  Health  Service  under  the  PPRS  (1)  when  given  at medical  symposia,  and 
even  then must  not  exceed  what  a  doctor would  normally  buy  for  himself.  In 
Luxembourg  the  law  forbids  firms  to  give  or  offer doctors  "any material 
benefits".  In France  there  is  a  ban  on  any  individual gift in  cash  or kind 
being  given  to  members  of  the medical  profession.  In  Italy doctors  are 
forbidden  to  accept  any  payment  in kind  from pharmaceutical  firms.  This 
does  not  rule  out hospitality at medical  symposia. 
(1)  Pharmaceutical Price Regulation  Scheme. 
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In Belgium,  Germany,  France  and  Luxembourg  there  are  legal provisions 
specifying  that  samples  can be  sent  to doctors  only if they  request  them. 
There  are  similar provisions under  the voluntary  codes  of  the  Industry in 
Ireland  and  the  United  Kingdom.  In Belgium medical  samples  are  not 
allowed  to  exceed  4% of the  turnover  of  that  product  from  the  end  of  the 
first year  of  its registration.  In Germany  records  have  to be  kept  of 
samples  which  are  sent  and  the  Industry has  undertaken  to  send  no  more  than 
six of  the  smallest  packs  of  each product  per written request.  In France 
no  samples  can be  sent after  the  product has  been  on  the market  for  two 
years.  In  the  United  Kingdom  samples,apart  from  those  given  for  recognition 
purposes,  can be  supplied  only  at  the written request  of  a  doctor  and  the 
cost  of  samples  other  that  for  recognition purposes is not  allowed  as  a 
charge  on  the  Health  Services  under  the  PPRS. 
In Denmark  only  one  sample  can be  sent  to  any  doctor  and  this  has  to be  in 
the  smallest  package,  and  it can be  sent  only during  the  first year  after 
the  product  has  been put  on  the market.  In  the Netherlands,  samples  can 
be  sent  only  on  the  introduction of  a  new  product  and  cannot  exceed  the 
amount  needed  to treat  three patients. 
e)  The  Quantity of  Sales  Promotion 
In France  and  Belgium  the  amount  and  proportion of  expenditure  on  sales 
promotion is examined  as  part  of  the  process  of regulating prices.  In  the 
United  Kingdom  the  Government  has  recently  announced  that it will  allow  as 
a  cost  in regulating profits  only  10  % of  turnover  spent  on  total 
sales  promotion  from  the  year  1979.  The  reduction is being phased  and  as 
the  first stage  a  reduction  of  2%  of  turnover  was  made  in 1977.  Any 
expenditure  above  the  prescribed  limit would  have  to  come  out  of  profits. 
There  are  no  restrictions  on  the  quantity of  sales  promotion  expenditure  in 
the  other  countries  in the  Community.  In Italy the  new  method  of  fixing 
prices  for  proprietary medicines  is  intended  to  curtail expenditure  on 
sales  promotion activities  and  the  distribution of  samples. 
2.  The  Pharmacist 
In  Ireland  and  France  pharmacists  can  supply  only  up  to  one  month's  supply 
of  a  pharmaceutical  prescribed under health  insurance.  In Italy  the  amount 
which  the  pharmacist  may  dispense,  to which  the  doctor must  conform when 
prescribing,  is  limited  to  two  packages  (containers)  of  the  same  proprietary 
product  or  alternatively  two  products  in individual packages,  except  for 
antibiotics  and  serums  which may  be  dispensed  in sufficient quantity for  two 
days  of  treatment  on  a  single  prescription.  Galenic  produc~and first-aid 
supplies may  also  be  included  in the  same  prescription within predetermined 
limits.  In  Germany  and  the  Netherlands  the  pharMacist  has  to  dispense  the 
smallest  packed  quantity when  no  indication is  on  the  prescription.  There 
are  no  limits  in  the  other  countries  of  the  Community.  The  renewal  of 
prescriptions is allowed  when  the  doctor has  authorised it in Belgium,  France 
and  Luxembourg.  In  Belgium one  prescription  cannot  exceed  two  months', 
and  in  France  six months' supply.  In  Luxembourg  a  patient has  to  have  a  copy 
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pharmacist  is authorised  to  renew it. 
In Germany  a  pharmacist  is expected  to  substitute  the  cheapest  generic 
product when  a  doctor  has  not  specified  a  particular manufacturer.  In the 
other countries  of  the  Community  the  pharmacist  has  to  dispense precisely 
the  product  which  the  doctor  has  prescribed  (in  the  case  of  the Netherlands 
the  product has  to be  in  the  "Regeling  en  Klapper"). 
3.  The  Patient 
There  are maximum  prices which retail pharmacists  can  charge  patients in all 
countries  in the  Community,  except  the  United  Kingdom  (for  products not 
provided  under  the  National  Health  Service).  These  are  also  the minimum 
prices  in Denmark,  Germany,  France,  Luxembourg  and  Italy.  In  the  other 
countries  the  pharmacist is free  to  charge  less.  In Belgium discounts 
are  limited  to  10  % · of  the  published  price  (or  on  what  remains  to  be paid 
by  the  insured  person)  and  can be  claimed  only at  the  end  of  the  year. 
Only  in  the Netherlands  are pharmaceuticals  free  of  charge  to all patients 
covered  by  health insurance.  In Ireland  free  pharmaceuticals  are  provided 
to  the  limited number  of patients  covered  by  the General Medical  Service 
Scheme  :  middle  income  group  patients  can  claim a  refund  for  any  expenditure 
on  pharmaceuticals  in excess  of  £  6.50 per month. 
In  Italy there  is at present  no  system under which  the  insured  person 
shares  the  cost,  but  for  a  number  of  the  proprietary products  listed in  the 
Health Care  Handbook,  the  insured is nevertheless  required  to make  a 
contribution.  Proprietary products  not  provided  free  of  charge  represented 
7.09  %of  the  total number  in  1976,  or  1.50 %of  the  total amount  invoiced. 
A more  general  system  of  charging is  to be  introduced,  granting exemption 
for  pensioners  and  other categories. 
Charges  are  flat rate in Belgium and  the United  Kingdom.  In Belgium  (from 
mid-January  1977)  a  charge  of  BFR  35  is made  for  generic preparations  and 
BFR  70  for  proprietary preparations.  These  charges  apply  to  the  smallest 
pack  size.  However,  Invalidity  and  Retirement Pensioners,  and  Orphans  and 
Widows  earning less  than  a  stated  amount  are not  charged  for  generic 
preparation  and  pay  only  BFR  40  for proprietary preparations.  In  cases  of 
chronic diseases  the  charge  is limited  to  BFR  40. 
In  the  United  Kingdom,  apart  from  contraceptives which  are  provided  free  of 
charge  under  the National Health  Service,  the flat rate  charge  is 20  pence  -
unchanged  since  1971.  Exempt  from  these  charges  are  : 
64 1.  Children under  the  age  of  16. 
2.  Expectant mothers  or others with  a  child  under  the  age  of  1  year. 
3.  Women  aged  60  or  over  and  men  aged  65  or  over. 
4.  Persons with  a  specified medical  condition requiring  continuous  medication 
5.  Persons  exempt  as  requiring  prescriptions  for  disablement  arising out of 
war  or  service  in  the  Armed  Forces. 
6.  Persons  and  their dependants  on  Supplementary Benefit  (public assistance), 
Family  Income  Supplement,  or  assessed  as  too  poor  to be  able  to pay. 
On  top  of  this  "prepayment  certificates"  can  be  purchased  for  £  2  covering 
a  period  of  6  months  or  for  £  3.50 covering  a  period  of  12  months. 
In Denmark  there  are  three rates  of  charge  :  25  %,  50  % 
or  100  %  according  to  the  therapeutic  significance  of  the  drug  and  to 
some  extent  the  price.  Persons with  low  incomes  in relation to  the  cost  of 
the  drug  are  exempt  from  the  charges.  In  Germany,  up  to July  1977,  the 
charge was  20  % of  the  cost  of  a  prescription up  to  a  maximum  charge 
of  DM  2.50.  Children whose  parents  are  insured  and  pensioners  were  exempt 
from  charges.  From  July  1977  the  charge  is  DM  1  for  each  prescribed  drug  : 
only children are  exempt.  Some  medicines  (e.g.  laxatives  and  cough  remedies) 
will not be  paid  for  by  the  sick  funds  in  future.  In France  the  normal 
charge  is  30%  of  the  cost.  But  from  December  1977  a  charge  of 
60  % has  been  introduced  for  certain "comfort"  pharmaceuticals  such  as 
laxatives.  For  some  particularly costly preparations  only  10%  of 
the cost  has  to be  paid.  No  charges  are  made  for  preparations  needed  to 
treat  chronic  diseases  or  illnesses arising  from  work.  War  veterans  and 
certain other  categories  are  exempt  from  charges.  In Luxembourg  the  patient 
has  to  pay  15  % of  the  cost,  but  some  pharmaceuticals  are  exempt. 
No  country  forbids  insurance  against  charges  for  prescriptions.  Only  in 
France  is  insurance  of  this kind  common. 
In France  and  Luxembourg  (except  for  manual  workers)  the  insured  person has 
to  pay  the  whole  cost of  the  prescription and  then  claim back  the  share 
covered  by  health insurance.  In  the  other  countries  (and  in the  case  of 
manual  workers  in Luxembourg),  the  health insurance  scheme  pays  the 
pharmacist direct.  In  the  case  of  Ireland  this  applies  only  to  those 
covered  by  the  General Medical  Services  Scheme. 
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1.  Economic  effects 
It is  obvious  that  in a  country where  there  are  no  price controls  or where 
controls  are  of minor  importance,  exports  and  imports will develop  freely, 
and will be  affected  only  by  the  policy  followed  in other  countries.  This 
is  the  case  in  Germany,  Denmark,  and  Ireland,  as  well  as  in Luxembourg, 
where  of  course  there  is  no  national  pharmaceutical  industry. 
Where  legislation affecting  the  prices  of  indigenous  pharmaceuticals  exists, 
two  opposing  forces  may  be  at work.  firstly,  a  moderate  internal price 
structure will  encourage  the  penetration of  external markets,  especially if 
competition exists between  several  exporting countries.  Secondly,  this  same 
price  structure will  lead  to  lower profit margins  for  sales made  within  the 
country which will  in  turn be  a  disadvantage,  since  laboratories will not 
be  able  to  allocate  enough  to  research  and  development,  and  hence will not 
be  able  to  develop  the  right  commercial  policy  for  breaking  into external 
markets.  When  prices  are  too  low  on  the  horne  market,  in other words,  the 
effect will be  felt  in  the export market.  Obviously  this  is  the view  taken 
by  the  pharmaceutical  industry.  Another  argument  bears  out  the  same 
hypothesis  :  when  the  importing  country  fixes  the  price  of  admission  or 
reimbursement  by  reference  to  the  price  in  the  country  of  origin,  low 
internal prices will mean  that  insufficient returns  are  made  on  products 
exported.  The  reports  on  Belgium,  France,  Ireland,  Italy  and  the  United 
Kingdom  all made  this  point;  the  Franch report,  however,  added  that despite 
the  restrictions  on price  increases  the  share  of  exports  in overall 
pharmaceutical  production in France  in recent  years  has  been  increasing.  In 
the  Netherlands,  export prices  are  usually below  those  for  the domestic 
market;  they  do  not  contain  an  element  for  amortization,  as  do  prices  for 
products  sold  in  the  country. 
The  British report  stressed  the  fact  that  the  strategy of  the multinationals 
will be  influenced  by  any  price  restriction in force  in  a  particular  country 
when  they  are  considering whether  to install production facilities there.  If 
regulations  are  too  restrictive,  they will be  disinclined  to  invest  there 
for  fear  of  the  price  structure  leading  to  too  low  a  platform for  export 
prices. 
Their  strategy  may  also be  influenced  by  any  regulations  in force  for 
health  insurance  repayments.  When  such  regulations  have  the  effect  of 
almost  totally prohibiting  the  import  of  patented  drugs,  firms  wishing  to 
enter  the  market  in that  country  have  no  alternative but  to  install 
laboratories  there.  This  occurs  to  a  notable  extent  in France. 
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effectiveness  of drugs  seem  to  have  little effect  on  imports  or exports  in 
a  particular country.  Italy and  the  United  Kingdom  mention exceptions.  In 
Italy health regulations  tend  to  favour  the  importation of drugs  which  have 
already been registered  in another  country;  this prior registration 
exempts  importers  from having  to  submit  drugs  to  the  tests  of  the health 
authorities.  New  Italian drugs  or  Italian equivalents  to drugs  already 
registered elsewhere would  both have  to  be  subjected  to  such  tests  for 
safety.  From  the  opposite  point of view,  the  British report  suggests  that 
internationally accepted  criteria for  safety  and  effectiveness  tend  to 
increase  exports.  Many  importing  countries  require  certification that  the 
product  has  passed  the  health regulations  in its country  of  origin. 
For  the  period  1965-1975,  a  comparison  of  the  income  of  dispensing 
pharmacists with  the  average  per  capita  income  for  all classes,  and  with 
the  income  of  similar professional  classes,  particularly those  treating  the 
sick  (doctors,  dentists,  etc.)  is,  indeed,  very difficult  to  establish. 
Replies were  sketchy  for  the  most  part.  In most  countries  available 
statistics were  not  adequate,  and  accurate  conclusions  cannot  be  drawn. 
The  British report  for  instance  stated  that  the  only  figures  available were 
those  drawn  from  NHS  files,  so  that  the  overall  figure  for  dispensing 
pharmacists'  income  is unknown  and  cannot  be  compared  with  that  of  other 
classes. 
The  Danish  report  noted  that  the  equalization  fund  referred  to  under  II B 
above  was  designed  to  eliminate  too  sharp  a  difference between  pharmacists' 
income  as  a  result  of  differences  in their  turnover.  If  the  aim was  that  a 
pharmacist's  average  income  should  be  equivalent  to  that  of  a  senior civil 
servent it would  not  seem  to  have  been achieved,  particularly in recent 
years. 
Only  Belgium  and  France  attempt  any  scientific evaluation,  but  even  this 
was  based  on  sample  surveys.  In  Belgium  an  unpublished  study  conducted  by 
the  National Statistical Institute  on  the basis  of  income  tax returns  for 
1966-1972  produced  the  following  figures  for  the  percentage  increase  in 
income  : 
overall 
blue  collar workers 
doctors 
dentists 
pharmacists 
+  59.97  % 
+  62.75  % 
+  86.40  % 
+  26.93  % 
+  52.97  % 
This  shows  that  pharmacists'incomes.haveincreased  a  little less  than those 
of  the  population as  a  whole,  and  much  less  than  those  of  doctors.  In 
absolute  terms,  in  1972  dispensing pharmacists'  incomes  were  roughly  five 
times those of  the  population  as  a  whole  and  20  % less  than  those  of 
independant  doctors. 
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organization,  for  the  period  1965-1975.  The  first  finding was  that  for  1975, 
in absolute  terms,  a  pharmacist's  average  income  was  10%  lower  than  that  of 
independent  doctors,  20%  higher  than  that of  upper  management  (engineers), 
and  more  than  seven  times  greater  than  the  per  capita  income  of  the 
population as  a  whole.  The  trend  in  income  over  the  period  1965-1975  has 
followed  an  irregular  curve.  Between  1965  and  1970,  the  increase  in 
pharmacists'  average  incomesat  relative prices was  more  than  that  of  the 
average  per  capita income,  but between  1970  and  1975  they  grew  less  rapidly 
(average  annual  growth  rate  1.60% against  4.30%  for  the  second  period). 
It seems  then  that  there has  been  a  slight  falling-off  in pharmacist's 
incomesrecently,  but  the  range  was  still wide  in  1975. 
For  the  other  countries,  reports were  based  on  impressions  rather  than 
accurate  statistics.  In  Germany  and  Denmark  pharmacists'  average  incomes 
have probably  increased  less rapidly  than those of  the  population as  a  whole 
or those of  other  similar professions.  The  German  report  notes  however  that 
the  large  number  of  new  pharmacies  which  have  opened  indicates  that 
expected  incomes  from  this profession are still considered  to be  more  than 
commensurate  with  the  training required,  despite  the  trend  mentioned  above. 
In  Ireland,  where  about  one million extra people  were  covered  by  some  form 
of  social  security in 1972,  the  number  of  customers  in pharmacies  increased 
by  about  50%  at  that  time.  Since  then however,  pharmacists'  incomes  have 
kept  in step with  incomes  of  other  classes.  Although  in Italy  the  average 
income  of  a  pharmacist  has  also  grown  less  slowly  than  that  of  actual 
incomes, this  depends  on  the  location of  the  pharmacy.  Luxembourg  notes  that 
the  average  income  of  pharmacists  is higher  than  that  of  the  population as 
a  whole  and  comparable with  the  income  of doctors  and  similar professions; 
the  report  gave  no  indication of  trends  in  these  various  incomes  over  the 
last decade. 
The  only  exception to this  general  tendency  is in the Netherlands,  where 
surveys  indicate  that pharmacists'  incomes  have  grown  much  more  rapidly  than 
incomes  in the  population  as  a  whole,  except  for  the  last  two  years. 
As  regards  the relationship between  general  employment  policy  and  the 
pharmaceutical  regulations  connected with production and  consumption, 
replies were  extremely varied.  Employment  statistics for  the 
pharmaceutical  sector  (laboratories, wholesalers,  pharmacists'  shops)  show 
that different  trends  occur  in each  area.  At  the industrial level, 
increased production has  been  accompanied  by  an  increase  in the  number  of 
people  employed  except where  concentration has  occured  (that is 
disappearance  of  small  labour-intensive units  in favour  of  large 
mechanized  or  automatically controlled production units, which  are more 
profitable).  Also,  the  increase  in imports  of patented  drugs,  that is 
finished  products,  has  the  effect of  cutting down  the  number  of people 
employed  in domestic  production.  In  the United  Kingdom,  however,  the 
number  of  people  employed  between  1963  and  1975  has  risen from  61  300  to 
74  800. 
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 The  narrowing  of profit margins  has  had  an effect,  notably,  on  employment  in 
the wholesale  sector  in some  countries.  It has  brought  about  concentration 
and  modernization,  with  a  consequent  reduction in  the  number  of  people 
employed.  In  other  countries,  mainly  in Germany  and  Italy,  the  number  of 
people  employed  in pharmaceutical wholesaling has  increased  probably because 
turnover has  increased  at  each wholesaler. 
As  far  as  chemists'  shops  are  concerned,  pricing regulations  have  had  little 
direct effect.  An  overall  increase  in consumption has  led  to  slightly more 
employment,  but  not  necessarily  amongst  wage-earners.  In  Belgium for 
instance  the  opening  of  a  large  number  of  new  pharmacies  has  lead  to  an 
increase  in  the  number  of  self-employed  chemist-owners,  with  a  corresponding 
decrease  in the  number  of  paid  employees. 
There  is  an  even  greater dearth of statistics in this  area.  For  indirect 
taxation,  if the rate  and  the  base  remain  unchanged,  the  amount  of  tax 
produced  is  a  direct  function of  the  amount  of  turnover. 
For  direct  taxation  on  the  other hand,  we  can  only make  certain  suppos~t~ons. 
In Germany  it seems  that high profits  are  made  all along  the  line,  with 
resulting high  tax revenue.  The  situation is reported  to  be  quite different 
in the  Netherlands  and  the  United  Kingdom.  In  the  former,  pharmaceutical 
regulations  encourage  concentration  in  the  industry.  This  results  in reduced 
tax revenue.  On  the  other  hand,  there  is  the  question  as  to whether 
concentration does  not  usually  lead  to  greater productivity,  a  decrease  in 
the  prime  manufacturing  cost,  and  hence  greater profits,  which will  in  turn 
bring in more  revenue  from direct  taxation based  on  them.  In  the wholesale 
sector,  on  the  other  hand,  the  two  factors  of  relatively narrow profit 
margins  and  increased  running  costs  (mainly  due  to  larger  stocks)  are  causing 
profits  to  be  smaller with  consequent  reduction  in direct  tax revenue. 
In  the  United  Kingdom  the  price regulation system has  the  effect  of 
restricting  the  increase  in  the value  of  sales,  and  consequently  of  the 
network  of  dispensing pharmacists.  This  in  turn  leads  to  a  lower  yield  from 
income  tax  although,  given  the  percentages  in question,  reductions  in the 
yield  are  small.  The  same  applies  to  the  pharmaceutical  industry,  at  least 
as  regards  the  share  of  production which  is  not  exported.  But it is 
difficult  to determine  the  precise effect of  price  regulation on profit. 
The  rate  of  return  on  pharmaceutical  sales  in the  United  Kingdom  between 
1955  and  1975  has  fallen  dram  31  % to  15.4  %,  in other words,  today it is 
the  same  as  for  large  United  Kingdom  companies  in general. 
The  United  Kingdom  report  indicates  that  "the  sale  of  medicaments  does  not 
result  in  tax revenue".  In reality,  the  situation is  probably not  so  cut 
and  dried,  since  pharmacists,  like all other  United  Kingdom  subjects,  pay 
income  tax  on  their earnings,  which will be  related directly to  the  volume 
of  business  which  they handle,  most  of it sales  of  pharmaceutical products. 
70 Although it was  not mentioned  in any  report,  it is  assumed  that  no  direct 
tax revenue  results  from  the  activities of public health organizations 
(municipalities in Italy),  or  private non-profit making  ones  (friendly 
societies in France,  cooperatives  in Italy), which  are  owners  of  pharmacies. 
It is difficult  to estimate if national pharmaceutical  regulations  are  liable 
to  influence  the  importance  (as  a  percentage)  of enterprises directly or 
indirectly controlled  from  abroad,  on  the  national markets.  Answers  to this 
question were  extremely vague.  In  two  countries,  however, (Italy  and  France) 
such effects certainly  seem  significant. 
In France it has  already been mentioned  that  foreign  imports  are virtually 
prohibited  and  thus  foreign  investments  in or  acquisition of  firms  in France 
has  resulted.  In  1975,  there were  88  firms  under  foreign  control 
(affiliates or majority shareholdings)  representing  43.6  % of  the  turnover 
in pharmaceuticals,  and  employing  37.9%  of  all labour  in  the  industry. 
In Italy  the virtual freezing  of  profit margins  combined with  obligatory 
refunds  to  social security organizations has  dealt harshly with  firms 
operating  largely  on  Italian soil.  The  situation,  combined  with  low  Italian 
labour  costs  and  generous  ceilings  for  the  prices of  imported  drugs  not 
having  Italian equivalents  has  encouraged  foreign  investment  in the  peninsula 
and  importation of  foreign patent  drugs  by  the  national  industry,  to  the 
detriment  of  the  production of  drugs  which  have  been developed  in Italy. 
In  the  United  Kingdom,  on  the  other  hand,  the  growing  share  of  foreign-owned 
firms  seems  to  be  due  less  to  the effects  of  regulations  than  to  other 
specific factors  such  as  language,  access  to markets,  the  cost  of  hiring, 
and  the  quality of  technical  staff  and  the  reputation of  the  medical 
profession.  Pharmaceutical  regulations  seem  to  have  affected  the  ratio of 
imports  to  total  sales  of  pharmaceuticals  rather  than  the  proportion of 
sales  realized  by  firms  under  foreign  control,  whether  they  are  situated  in 
Britain or  not. 
No  report  was  able  to give  statistics  showing  whether  foreign  capital 
invested  in  the  pharmaceutical  industry  in their country  carne  from  inside  or 
outside  the  EEC,  for  the period  of  the  last  ten years.  The  reports  for 
Italy,  the  United  Kingdom  and  France  did  give  the  following  figures.  In  the 
case  of  Italy  the  situation relates  to  1974. 
71 Number  of  firms  % of national market 
ITALY  ---
EEC  --
Belgium  2  0.4 
France  10  4.5 
Germany  15  12.1 
Netherlands  3  1.2 
United  Kingdom  5  5.3 
TOTAL  35  23.5 
Non-EEC 
Australia  1  0.1 
Austria  1  0.1 
Portugal  1  0.7 
Switzerland  7  10.1 
United  States  29  19 
TOTAL  39  30.0 
In  the  case  of  the  United  Kingdom  a  similar  table relating to  1975  gives 
the  following  : 
Number  of  firms  % of national market 
UNITED  KINGDOM 
EEC  --
France  3  5.6 
Germany  5  8.2 
Netherlands  3  2.5 
TOTAL  11  16.3 
(Other  :  under  1  %) 
Non-EEC 
Sweden  2  1.1 
Switzerland  4  12.2 
United  States  24  36.5 
TOTAL.  30  49.8 
72 In Italy  and  the  United  Kingdom  over half  the  national market  has  been 
cornered  by  foreign-owned  firms. 
In France  the  data are  for  1976  and  relate  to  firms  with  a  majority  of 
foreign-owned  capital  and  foreign  branches. 
Number  of  firms  % of national market 
FRANCE 
EEC  ---
Germany  22  12.8 
Netherlands  7  2.1 
United  Kingdom  14  3.8 
TOTAL  43  18.7 
Non-EEC 
Switzerland  7  7.5 
United  States  32  17.6 
Other  8  1.6 
TOTAL  47  26.7 
2.  Effects  on  health 
In all countries  the  influence of  the  freedom  of prescription on  the  status 
of health of  the  whole  population has  been recognized  as  very  complex.  The 
question may  be  examined  both  theoretically  and  practically. 
Theoretically  speaking,  freedom  in prescribing without  any  controls  carries 
in itself certain risks,  both  to health,  and  of  an  economic  and  social 
nature.  In  Belgiu~ the  problem is most  acute  for medication which  is 
complicated  to  use  (specialized knowledge  needed  by  the doctor,  special 
equipment)  or  for  drugs  which  have  a  low  efficacy/safety rate  (wide-
spectrum antibiotics,  some  anti-cancer drugs).  The  same  point was  mentioned 
in the  Luxembourg  report.  The  complexity  of  certain medicaments,  especially 
the  possibility of  side-effects,  was  such  that  the risk of making  them 
available  to all general practitioners perhaps  outweighed  their value.  In 
one  particular case,  the risks  appeared  to be  so  great  that  the  drug was 
withdrawn  from  the  market  by  the manufacturer,  despite its undeniable 
efficacy.  A better solution than withdrawing it entirely might  have  been 
to restrict its use  to specialists or  to  GP's  working  in hospitals,  or  to 
both. 
73 As  both  the  British  and  Italian reports made  clear,  clinical freedom  imposes 
grave  responsabilities  on  the medical profession.  Not  all eventualities may 
have  been foreseen before  releasing  the  drug  on  the  market  :  some  drugs  may 
have  very  rare  side-effects which  did  not  come  up  during  tests;  in 
combination with other medication,  interactions which  were  not  foreseen 
during  tests may  occur.  Some  patients may  exhibit hypersensitivity beyond 
what  could  have  been foreseen. 
Further,  doctors  are  often unaware  of what  medication has  been prescribed 
for  their patients previously by  other doctors. 
There  are  two  possible  approaches.  The  first  tends  to  confine  freedom  of 
prescription as  much  as  possible.  This  policy is followed  in Denmark  where 
the  number  of  specific drugs  marketed  is  limited  to  1  200  approximately,  and 
by  subjecting prescriptions  to very strict rules.  Without  going  into detail 
we  will mention  that medicines  are broken down  into  four  categories 
according  to risk  (depending  on  toxicity and  dependence).  In  the  case  of 
categor~ A,  (such  as  morphine  and  equivalent  drugs),  a  prescription is  noted 
on  spec1al  numbered  forms  issued  by  the Ministry of  Health,  a  copy  of which 
is sent  to  the  Ministry  of Health  and  put  into  the  computer.  For  the 
others,  no  copy  is sent  to  the  Ministry but  depending  on  the  risk, 
dispensing  is restricted  (one  time;  renewal  is possible within one  year; 
purchase without  prescription).  Certain particularly toxic medicines  can 
be  prescribed  only by  hospitals.  The  increased  security has  forced  some 
drug  addicts  who  previously obtained  supplies by putting pressure  on  their 
doctors  to  have  recourse  to  illegal  sources. 
The  second  approach  is not  to restrict freedom  of prescription but  to work 
on practitioners  by  providing more  information or  by  carrying out  subsequent 
checks. 
In  the first place  then  the  doctor's  professional  conscience must  be  appealed 
to.  In  the  United  Kingdom  and  Ireland doctors  are  invited, but not  legally 
bound,  to  notify  any  secondary reaction to  the  Committee  for  Drug  Safety. 
In Ireland  a  Council  of  the Medical Register  shortly  to  be  set  up  under  the 
Ministry of  Health will be  empowered  to  prohibit doctors  from  prescribing 
products  which  may  be  habit-forming if it has  been proved  that  these  drugs 
were  prescribed without  grounds  or  in excessive  amounts.  Also  in Ireland, 
committees  have  already been set  up  in hospitals  to  assess  the  efficacy of 
some  drugs  in a  hospital  environment.  In France  there  is  a  pharmaco-
vigilance  service  under  the  central pharmaceutical  department  of  the 
Ministry  of  Health  to which  doctors  can notify drugs  which  produce  certain 
ractions  that  were  not  foreseen during  the  trial period.  In  Belgium  a 
similar  system has  just been  instituted. 
In  Italy health  insurance  organizations  attempt  through  their drug  list 
(''p1 11ntuario")  to  limit  the  use  of  or  eliminate entirely drugs  whose  usage 
is  complicated.  Preliminary  consultations  take  place  in special  or hospital 
centres,  "which is  a  means  not  of  restricting the  freedom  of  the  GP,  but  of 
rationalizing action in the  therapeutic  area". 
74 But  as  far  as  doctors  themselves  are  concerned,  the  best  course  is  to keep 
up  to date with  new  scientific information after their studies,  and  even 
later on  to  take  refresher  courses. 
Even  so,  negligence  on  the part of  the medical  profession can bring about 
sanctions.  In  the  United  Kingdom,  for  example,  these  sanctions  can  amount 
to disciplinary measures  by  the  national health service  or may  fall under 
the  civil code.  But  the  small  number  of  actions which  are  brought  under 
these  two  sets  of provisions  seems  to  indicate  that  the  consequences  of 
clinical  freedom  for  the health of  the British patient are not  particularly 
harmful. 
The  Luxembourg  report put  the responsibility for  safeguarding  the  general 
interest fairly  and  squarely  on  those who  demand  the  right  to clinical 
freedom,  since it is  a  responsibility that  springs directly  from  that 
privilege.  When  this responsibility is  too  great  - for  example  for  drugs 
which  are especially difficult  to prescribe  - then it is quite  understandable 
that  legislation must  intervene  to  limit that freedom  in such  cases. 
In  the  German  report  stress was  laid  on  information  and  direct action by  the 
public authorities  and  it contained various  proposals  that would  limit  the 
risks  to  the  patient but would  not  curb  clinical freedom.  The  risks  could  be 
reduced  by  a  standard  information  system on  secondary effects  that would 
function rapidly  and  immediately  transmit  warnings  to all doctors.  It 
would  also  seem necessary  to  subject  the  content  of  prescriptions  to  some 
control.  It would  be  advisable  to withdraw  from  the market  preparations 
that  can have  no  healing effect  (medication which  combines  different active 
substances). 
In  the  last analysis,  even when  a  prescription is presented, it is up  to  the 
dispensing  chemist,  who  has  a  moral  if not  legal responsibility,  to  notify 
anything  abnormal. 
In  general it is recognized  that  self-medication is liable  to  induce  dangers 
which  require  considerable  caution.  Only  the  Belgian report  seems  to 
indicate  that  the  freedom which  the public has  to purchase  drugs  without 
prescription does  not  pose  major  problems  that  could  be  solved  by  prohibiting 
sales without prescription.  Regulations  ensure  that drugs  shall be 
delivered  only  by  people holding professional qualifications,  bound  by  their 
professional obligations  and  code  of ethics.  Furthermore,  the  number  of 
drugs  which  may  be  delivered without prescription is  fairly  limited.  In 
Denmark  threats  to health are  known  to exist, but  are  seen as  being minor 
ones. 
In Italy,  Ireland,  the United  Kingdom  and  Luxembourg,  on  the  other hand,  the 
problem is  seen as  more  serious.  Certain products  on  free  sale  can be 
dangerous  in some  circumstances,  though  harmless if taken  in moderation.  The 
British report  cites  the  example  of  certain analgesics  such  as  aspirin and 
Paracetamol.  "When  taken  in  large doses,  whether  intentionally or not, 
these  medicaments  present  a  health hazard.  Aspirin  and  Paracetamol  occupy 
75 the  fifth  and  sixth places  respectively  on  the  list of  drugs  whose  inten-
tional use  necessitates hospitalization.  Junior  aspirin tablets,  also  on 
free  sale,  constitute  one  of  the  main  causes  of  hospitalization due  to 
unintentional  overdose." 
Dangers  arise not  only  from  single massive  doses,  but  from  repeated  use 
leading  to dependence.  This  can  occur with  antihistamine  preparations  or 
those  containing  small  amounts  of  opium.  For  products  which  are  on  sale 
only  in pharmacies  (even  though  a  prescription is not  required)  the 
pharmacist  can  ensure  a  degree  of  control  and  give  advice  to  the  user.  But 
the  British report went  on  to  state  that it is no  easier  for  the  pharmacist 
than  for  the  doctor  to  foresee  all possible  interactions which  may  occur,  and 
finally,  refusal  to  sell  on  the  part of  one  pharmacist may  only  lead  to  the 
person obtaining  the  drug  from  another. 
The  German  report  also  pointed  out  that unrestricted  self-medication  can 
have  no  good  effects  on  public health.  There  are  three  problems 
- the  danger  of addiction which  is not  confined  to  toxic drugs; 
- the  widespread belief in  the unlimited  possibilities  of  pharmaco-therapy 
that  is deliberately reinforced  by  advertising on  the  part of  the  supplier; 
- the risk  that very  serious  illnesses will not  be  spotted  and  no  treatment 
given  for  a  long  time. 
The  report  concludes  that  self-medication should  be  allowed  only within 
certain limits,  for  example,  innocuous  medicines  for  coughs  and  headaches. 
The  problem can be  solved  to  some  extent by  limiting  the  number  of  products 
which  can be  sold off prescription,  according  to the  therapeutic  category 
into which  they fall.  Recent  trends  in Italy have  been  towards  limiting 
the  number  of certain categories  of  drugs.  The  patient is protected  against 
himself  and  against  a  certain type  of  popular pseudo-scientific  journalism, 
which  he  may  not  evaluate  correctly.  But  this  type  of  policy is hard  to 
carry  through  in  a  single  country.  The  Luxembourg  report  pointed  out  that, 
even within  the  EEC,  legislation varied  from  one  country  to  another. 
For national  legislation in this  area  to  be  effective,  legislation in 
neighbouring- and  especially bordering- countries must  be,  if notthe  same, 
at  least very close;  unless  it is,  someone  from  the  country with  the 
stricter  laws  will not  have  to traval far  to obtain  the  drug which  he 
whishes  to misuse  :  this would  multiply  the  protection afforded by  placing 
the  drug  under  surveillance in the first  country. 
Secondly,  to place  a  product  - on health  grounds  - in the  category of  those 
which  cannot  be  procured without  a  medical prescription may  have  serious 
economic  consequences  for manufacturers.  According  to  the  Luxembourg  report, 
it has  the  effect  of  reducing by  one  third  the distribution of  a  product 
that was  previously freely obtainable.  In such  a  case  the authorities may 
have  t.o  decide between conflicting health  and  economic  considerations. 
76 Thirdly,  as  regards  social security cover,  a  major  infringement  of  patients' 
rights  to  purchase  products without prescription may  entail additional 
expenditure  for  sickness  insurance  organizations  due  to  the  fact  that  the 
patient would  be  obliged  to  consult  the  doctor  each  time. 
On  this  point  a  solution was  found  under  the partial agreement  of  the  Council 
of  Europe  on  which  the nine  EEC  countries  are  represented.  The  resolution 
could  perhaps  be  worded  in more  restrictive  terms. 
The  essential  problem here  is  the  level of  education in matters  of  health 
among  the  general public.  In  Ireland  awareness  of  this  problem has  lead  to 
the  setting-up  of  a  bureau  of health education,  in conjunction with members 
of  the  medical  and  pharmaceutical professions.  Its  aim is  to  try  and  reduce 
the  demand  for  and  use  of  products  of  no  value.  Perhaps  the  measures  to  be 
taken depend  on  the  extent  to which  the  risks  are understood.  In Britain 
it is  thought  that  ''given  the  quantity of pharmaceutical products  sold off 
prescription and  the  inevitable  occurrence  of  certain side-effects,  the 
problem does  not  have  to be  regarded  too  seriously."  In  Ireland  on  the 
other  hand  the development  of  self-medication "is  leading  to  a  considerable 
amount  of  sickness  and  in  some  cases  to death",  as well  as  to  a  large  number 
of  cases  of  hospitalization mainly  through  "prolonged  ingestion of  some 
analgesics,  antibiotics  and  hypnotics". 
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Although  the data collected for  the  countries  of  the  Community  were  not 
complete  or  exactly comparable,  the following  points  emerge  from  the 
statistical analysis  : 
1.  In all countries  of  the  Community  the  cost of  pharmaceutical  consumption 
has  been  increasing in absolute  terms  over  the period  1966  to  1975.  (This 
was  believed  to  be  the  case  in Ireland,  even  though  figures  were  not 
available). 
2.  As  a  proportion of  national  income,  pharmaceutical  consumption  (including 
tax)  has  been rising slightly in most  countries  over  this period,  has 
changed  little in others  and  fallen slightly in one  country  (the  United 
Kingdom). 
3.  In all countries  for  which  information was  available,  pharmaceutical 
consumption  appears  to be  falling as  a  percentage  of  total current 
expenditure  on  health services.  But  this  has  occurred  over  a  period during 
which  there  has  been  a  substantial  growth  of  expenditure  on hospital  and 
specialist  services. 
4.  In countries which maintain price  indexes  for  pharmaceuticals  based  on 
baskets  of  products,  prices of pharmaceuticals  have  risen less  than retail 
prices.  (This  is not  the  case  in Germany  but  the  index  contains  few  items 
and  has  not  been recently revised).  Thus  the  increase  in consumption  is 
not  due  simply  to  increases  in the  prices  of  existing products  :  the  volume 
of  consumption has  increased  and,  in addition,  old  products  have  been 
replaced  by  new  products  which  are  generally more  expensive.  In  some 
countries  the  extension of health insurance  to  cover  a  wider  section of  the 
population may  have  contributed  to  greater  consumption.  In many,  but  not 
all,  countries  the  number  of  prescription items  provided  per  person has 
been  increasing. 
5.  There  are  substantial variations between  countries  in the  role  of 
pharmaceutical  consumption both  in relation to  the  total cost of health 
services  and  in relation to national  income. 
a)  As  a  proportion of  the  current  cost  of health  services it amounted  in 
1975  to  over  a  third  in Italy,  about  a  quarter in France  and  less  than 
a  fifth  in  the  other  countries  for  which  data were  available.  The 
lowest  percentages were  in the  United  Kingdom  (under  14  %)  and  Denmark 
(under  11%  in 1975). 
b)  As  a  percentage  of national  income  the variation in  1975  was  from  over 
2  % in Italy to  under  1  % in Denmark  and  the  United  Kingdom. 
79 6.  Wide  variations  in the  average  number  of prescription items  provided  per 
person per year  - from  4  1/2  in the  Netherlands  (1974)  to 21  in Italy  (1975 
under  INAM  scheme  by doctors  paid  by  fee-for-service)  - appear  to  go  a  consi-
derable way  towards  explaining differences  in the relative cost between 
countries.  The  number  of  prescription items  per person per year  was  found 
to be  lower  in the  three  countries where  general practitioners were  not  paid 
on  a  fee-for-service basis  than in the  four  othe~ countries  (for which data 
were  available)  where  doctors  were  paid  on  a  fee-for-service basis. 
The  analysis  of  the policies  pursued  by  the  Member  States  and  the  effects 
of  these  policies  cannot  lead  to positive  conclusions  relating to  the 
influence which  these  policies have  on  the  costs  of pharmaceutical 
consumption  in each  of  the States. 
This  would  require  a  much  more  detailed  study  as well  as  better factual 
information  than was  at  the  experrn'  disposal. 
Nevertheless,  it is evident  that  in the  pharmaceutical  sector  two  different 
preoccupations  inspire  the measures  which  have  been  taken  and  these  may  be 
both  complementary  and  contradictory. 
A.  HEALTH  PROBLEMS 
These  intervene  at several  levels  : 
- not  everything  can be  put  on  the  market  every  country has  procedures 
(authorization,  approval ...  )  which  aim  to  ensure  that  the  quality,  the 
effectiveness  and  the  safety of  a  product  are maintained  for  its 
prescribed  uses.  (Directive  65/65/EEC  of  January  1965)  (1); 
- a  watch must  be kept  for  side effects which become  apparent  only with use 
and  appropriate  action  taken where  necessary; 
- the  different sectors  of  the  pharmaceutical field  cannot  be  left in the 
hands  of  just anybody.  Whether  it be  manufacture,  prescription,  or 
distribution, all these  specialities are  normally  in the hands  of  persons 
who  have  pursued  studies  that were  often specialized, of  a  lengthy duration 
and  enabling  them  - in principle  - to  assume  a  certain degree  of 
responsibility.  Certain exceptions exist  in  the  distribution sector  in 
some  countries  and  for  certain medicines  which  are  less  dangerous  than 
others; 
- not  everyone  can be  left to prescribe  just anything  :  for  certain 
medicines,  prescriptions  are  registered.  This  enables  public authorities 
to  collect data  and  also  to  intervene  in individual  cases  where 
necessary; 
(1)  Completed with  the  addition of  Directives  75/318  and  75/319  which  carne 
into effect  in November  1976. 
80 - the  patient  cannot  be  left to buy  everything freely;  in general, 
countries  limit  self-medication to  a  greater  or  lesser  extent; 
- free  competition cannot  exist between prices  at  the retailer level,  so 
that  the  patient  does  not  encounter  any  danger; 
finally,  excessive  geographical  limitations  should  not  be  allowed  to  remain 
so  that  each  citizen has  access  to pharmaceutical products. 
With  respect  to  the  above,  two  observations  can be  made  : 
In  the  first  instance,  all of  these  points  also  have  economic  implications, 
as  we  shall  see  later.  Both  preoccupations  can  come  into play at  the  same 
time. 
It must  also be  noted  that  on  all  these  points national  op1n1ons  can differ 
appreciably.  There  is  the  risk  that  the  transparent  nature  of  frontiers 
will deprive  national  legislation of  its role  of protector  in the  field  of 
public health if the  legislation of  the  bordering  country is  less  stringent. 
It would  therefore  seem particularly desirable  to  pursue  the  task  of 
harmonization at  Community  level. 
B.  THE  ECONOMIC  U1PLICATIONS  FOR  THE  COMMUNITY  AT  LARGE 
The  burden  of  cost  of  pharmaceutical  consumption  in each  country  presents  a 
problem  as  far  as  concerns  that part  of  the  cost which  is borne  by  the 
community  at  large. 
An  examination  of  the policies which  have been pursued  during  the  ten year-
period  (1966-1975)  demonstrates  that  countries have  tried  to  intervene  in 
controlling both  of  the factors  which  constitute cost,  i.e.  price  and  volume. 
1.  The  action  taken with regard  to prices 
In no  country  are  the prices  of  pharmaceutical  products  totally free  at  any 
of  the  levels  where  they  arise.  Naturally,  the  price  control  framework 
varies  according  to  the  country. 
The  price  control  framework  - in most  countries  at  least - comes  into play 
at  the production level  : 
- by means  of  price  limits which  are  either based  on  the price  of  the 
product when  it leaves  the  factory  or  on  the  presentation size  of  the 
products; 
- or  by means  of  an  a  postePioPi  control  on profits; 
- or  by  limiting certain components  of  the  retail price,  such  as  the 
distribution of  samples  or  the percentage  spent  on  publicity. 
Price  control  can also intervene  at different stages  in the  commercialization 
of  the product. 
81 In principle,  if the  public authorities  do  not  object  to price  competition 
at  the  production stage,  provision for  such  competition does  not exist in 
all countries  at  the wholesale  level  (particularly where  a  single, 
compulsory profit margin is applicable  to all)  and  is virtually non-existent 
at  the  retail level,  where  all are  subjected  to  a  single,  compulsory profit 
margin  for  all products or all homogeneous  groups  of products. 
Along  the  same  lines,  some  countries  have  limited  the possibilities  for 
creating new  pharmacies  in such  a  way  as  to  ensure  sufficient  income  for 
the  pharmacy  taking  into account  the  applicable profit margin  for 
distribution. 
But  even  in those  countries where  price control  operates,  price  levels  are 
never  fixed  with  the  sole objective  of  limiting public expenditure  and 
social  security expenditure  in the  pharmaceutical  field.  It is  a 
sufficiently important  economic  sector affecting enough  employed  persons  for 
the  social  (employment  and  income)  and  political  (pressure  groups) 
consequences  not  to  be  lost  from  view.  Likewise,  both  these  preoccupations 
can be  brought  into play  together. 
The  decisions which  are  taken generally  take  acount  of  the  other factors 
which  can  have  a  contradictory effect  on  price  levels  and  either provoke 
price  increases  or  limit  such  increases.  The  main  factors  to be  considered 
are  : 
- the  balance  of  payments  with  the  outside world  : 
•  the  function  of  the  relationship between export prices  and  internal 
market  prices 
•  on  account  of  the  income  obtained  through  taxation derived  from  export 
profits 
•  on  account  of  the  tendency  to  favour  or  disfavour  the  implantation of 
foreign  firms 
•  on  account  of  the  income  and  expenditure  arising  from  the  exploitation 
of  patents  or  licences; 
- the vitality of  national  research  ("independence" with  regard  to  foreign 
suppliers); 
- the  contribution which  the  pharmaceutical  profession  as  a  whole  brings  to 
the  growth  of  the  gross  national  product  and  national  income; 
- employment  problems; 
- investment  development  on national  territory. 
82 2.  The  action  taken with  regard  to prescriptions 
Whilst  most  countries  have  taken measures  in this field  (limiting  the 
duration of  treatment  or  the  availability of  repeat  prescriptions),  the 
problem has  not  been satisfactorily resolved.  Numerous  medicines  are 
prescribed  and  are  either never  used  - which  constitutes  a  waste  - or  are 
later  used  in self-medication,  or  are  thrown  away,  which  causes  health 
problems.  Any  solution which  is proposed  limiting prescriptions,  is  seen 
as  an  infringement  of  the  liberties  of  the  individual  and  in addition raises 
highly  sensitive control  problems  which  are  felt  to  be  a  further  infrigement. 
Consequently  this  problem is  as  much  a  political one  as  a  technical  one. 
In  the  main,  public authorities  can  intervene 
- either by  producing  a  limited list of  products  that will be  reimbursed  or 
taken in charge; 
- or  by  taking  sanctions  against practitioners who  prescribe expensive 
medicines  which  are  not  therapeutically  indispensable  :  in most  of  the 
nine  countries  a  system  of  checking prescriptions  is  already being 
operated. 
3.  Action  taken  to  change  attitudes 
Everything which  increases  the  charges  borne  by  the  insured  person  (the 
existence  of  a  contribution,  the  cost  of  this  contribution,  the  necessity  of 
having  to  advance  the  full  amount)  is undertaken in every  country  (with  the 
exception of  the Netherlands)  with  a  view  to  restraining  the patient's 
tendency  to  increase  consumption.  The  individual  reports  do  not  quantify 
the  real  consequences  of  this  increase  and  it is  impossible  to  know  if, in 
taking  such  a  decision,  the  public authorities  have  modified  the  attitudes 
of  the  insured  person. 
Those  measures  which  have  been  judged  by  the  national rapporteurs  to be  the 
most  effective  are  those  which  aim  to modify,  in  the  long  term,  the 
attitudes  of  those  concerned  making  them  aware  of  the  economic  and  health 
problems  which  are  raised. 
83 - with doctors 
•  outside  the  care  system  (training, publicity); 
•  within the  care  system  (reducing "pressure"  from  the patient by 
abolishing  the  system of  separate  payments  for  each  intervention); 
- with patients 
•  (health education,  control  and  sanctions). 
It would  seem  that relatively little has  so  far  been  done  in this  field  and 
that  any  action that was  undertaken would  produce positive results,  both at 
the  health  and  the  economic  levels. 
84 STUDY  OF 
PHARMACEUTICAL  CONSUMPTION 
IN  MEMBER  STATES 
QUESTIONNAIRE 
(Third  Complete  version - March  1977) P
A
R
T
 
O
N
E
 
-
S
T
A
T
I
S
T
I
C
S
 
I
.
 
T
R
E
N
D
 
O
F
 
P
H
A
R
M
A
C
E
U
T
I
C
A
L
 
C
O
N
S
U
M
P
T
I
O
N
 
(
P
l
e
a
s
e
 
f
o
l
l
o
w
 
d
e
f
i
n
i
t
i
o
n
 
p
r
o
v
i
d
e
d
.
 
I
f
 
d
a
t
a
 
i
s
 
n
o
t
 
a
v
a
i
l
a
b
l
e
 
w
h
i
c
h
 
c
o
n
f
o
r
m
s
 
t
o
 
t
h
i
s
 
d
e
f
i
n
i
t
i
o
n
,
 
p
r
o
v
i
d
e
 
a
v
a
i
l
a
b
l
e
 
d
a
t
a
 
o
n
 
a
 
d
i
f
f
e
r
e
n
t
 
d
e
f
i
n
i
t
i
o
n
 
a
n
d
 
p
l
e
a
s
e
 
e
x
p
l
a
i
n
 
d
e
f
i
n
i
t
i
o
n
 
u
s
e
d
)
.
 
F
i
n
a
l
 
C
o
n
s
u
m
p
t
i
o
n
 
i
n
 
c
u
r
r
e
n
t
 
P
r
i
c
e
s
.
 
C
u
r
r
e
n
c
y
 
U
n
i
t
 
•
.
•
 
(
M
i
l
l
i
o
n
,
 
B
i
l
l
i
o
n
,
 
e
t
c
.
)
 
1
 
2
 
3
 
4
 
5
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
P
u
r
c
h
a
s
e
d
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
O
b
t
a
i
n
e
d
 
w
i
t
h
 
a
 
T
o
t
a
l
 
C
o
s
t
 
o
f
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
w
i
t
h
o
u
t
 
P
r
e
s
c
r
i
p
t
i
o
n
s
 
P
r
e
s
c
r
i
p
t
i
o
n
 
C
o
n
s
u
m
p
t
i
o
n
 
t
o
 
H
e
a
l
t
h
 
I
n
s
u
r
a
n
c
e
 
(
1
)
 
Y
e
a
r
 
P
h
a
r
m
a
c
i
e
s
,
e
t
c
.
 
H
o
s
p
i
t
a
l
s
 
(
2
)
 
I
n
c
.
 
T
a
x
 
E
x
c
.
 
T
a
x
 
I
n
c
.
T
a
x
 
E
x
c
.
T
a
x
 
I
n
c
.
T
a
x
 
E
x
c
.
T
a
x
 
I
n
c
.
T
a
x
 
E
x
c
.
T
a
x
 
I
n
c
.
 
T
a
x
 
E
x
c
.
 
T
a
x
 
(
a
)
 
(
b
)
 
(
a
)
 
(
b
)
 
(
a
)
 
(
b
)
 
(
a
)
 
(
b
)
 
(
a
)
 
(
b
)
 
1
9
6
6
 
1
9
6
7
 
1
9
6
8
 
1
9
6
9
 
1
9
7
0
 
1
9
7
1
 
1
9
7
2
 
1
9
7
3
 
1
9
7
4
 
1
9
7
5
 
1
9
7
6
 
E
s
t
.
 
1
9
7
7
 
P
r
o
j
.
 
1
9
7
8
 
P
r
o
j
.
 
1
9
7
9
 
P
r
o
j
.
 
1
9
8
0
 
P
r
o
j
.
 
(
1
)
 
I
f
 
p
o
s
s
i
b
l
e
,
 
s
p
e
c
i
f
y
 
i
f
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
 
c
o
n
s
u
m
p
t
i
o
n
 
a
r
i
s
i
n
g
 
f
r
o
m
 
a
c
c
i
d
e
n
t
s
 
o
f
 
w
o
r
k
 
a
n
d
 
o
c
c
u
p
a
t
i
o
n
a
l
 
d
i
s
e
a
s
e
s
 
i
s
 
i
n
c
l
u
d
e
d
 
i
n
 
t
h
e
s
e
 
f
i
g
u
r
e
s
.
 
I
f
 
p
o
s
s
i
b
l
e
,
 
g
i
v
e
 
a
v
a
i
l
a
b
l
e
 
d
a
t
a
 
f
o
r
 
t
h
e
s
e
 
t
w
o
 
i
t
e
m
s
.
 
I
f
 
n
e
c
e
s
s
a
r
y
,
 
s
p
e
c
i
f
y
 
t
h
e
 
c
o
s
t
 
o
f
 
p
r
e
s
c
r
i
b
e
d
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
p
a
i
d
 
b
y
 
t
h
e
 
p
a
t
i
e
n
t
 
h
i
m
s
e
l
f
.
 
(
2
)
 
G
i
v
e
,
 
i
f
 
p
o
s
s
i
b
l
e
,
 
t
h
e
 
a
v
a
i
l
a
b
l
e
 
d
a
t
a
 
a
n
d
 
a
n
y
 
e
x
p
l
a
n
a
t
i
o
n
 
o
f
 
t
h
e
i
r
 
c
o
n
t
e
n
t
 
a
n
d
 
t
h
e
i
r
 
a
c
c
u
r
a
c
y
.
 D
E
F
I
N
I
T
I
O
N
S
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
T
a
x
 
O
b
t
a
i
n
e
d
 
w
i
t
h
o
u
t
 
p
r
e
s
c
r
i
p
t
i
o
n
 
O
b
t
a
i
n
e
d
 
w
i
t
h
 
a
 
p
r
e
s
c
r
i
p
t
i
o
n
 
P
h
a
r
m
a
c
i
e
s
 
e
t
c
.
 
H
o
s
p
i
t
a
l
 
H
e
a
l
t
h
 
I
n
s
u
r
a
n
c
e
 
E
x
c
l
u
d
e
 
V
e
t
e
r
i
n
a
r
y
 
P
r
o
d
u
c
t
s
.
 
I
n
c
l
u
d
e
 
m
a
t
e
r
i
a
l
 
f
o
r
 
I
n
j
e
c
t
i
o
n
.
 
V
A
T
 
a
n
d
 
L
o
c
a
l
 
S
a
l
e
s
 
T
a
x
.
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
a
c
t
u
a
l
l
y
 
o
b
t
a
i
n
e
d
 
w
i
t
h
o
u
t
 
a
 
p
r
e
s
c
r
i
p
t
i
o
n
 
e
v
e
n
 
t
h
o
u
g
h
 
a
 
p
r
e
s
c
r
i
p
t
i
o
n
 
c
o
u
l
d
 
h
a
v
e
 
b
e
e
n
 
o
b
t
a
i
n
e
d
;
 
w
h
e
t
h
e
r
 
p
u
r
c
h
a
s
e
d
 
i
n
 
P
h
a
r
m
a
c
y
 
o
r
 
o
t
h
e
r
 
s
h
o
p
 
(
e
.
g
.
 
s
u
p
e
r
m
a
r
k
e
t
)
.
 
E
n
t
e
r
 
t
o
t
a
l
 
r
e
c
e
i
p
t
s
 
f
o
r
 
t
h
e
s
e
 
p
u
r
c
h
a
s
e
s
 
i
n
c
l
u
d
i
n
g
 
o
r
 
e
x
c
l
u
d
i
n
g
 
T
a
x
.
 
E
n
t
e
r
 
a
l
l
 
o
b
t
a
i
n
e
d
 
w
i
t
h
 
a
 
p
r
e
s
c
r
i
p
t
i
o
n
 
e
v
e
n
 
t
h
o
u
g
h
 
s
o
m
e
 
c
o
u
l
d
 
h
a
v
e
 
b
e
e
n
 
p
u
r
c
h
a
s
e
d
 
w
i
t
h
o
u
t
 
a
 
p
r
e
s
c
r
i
p
t
i
o
n
.
 
E
n
t
e
r
 
t
o
t
a
l
 
r
e
c
e
i
p
t
s
 
f
o
r
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
 
s
a
l
e
s
 
e
v
e
n
 
i
f
 
s
o
m
e
 
p
a
r
t
 
p
a
i
d
 
b
y
 
p
a
t
i
e
n
t
 
o
r
 
h
e
a
l
t
h
 
i
n
s
u
r
a
n
c
e
 
o
r
 
h
e
a
l
t
h
 
s
e
r
v
i
c
e
.
 
I
n
c
l
u
d
e
 
a
n
y
 
h
o
n
o
r
a
r
i
a
 
o
r
 
f
e
e
s
 
p
a
i
d
 
t
o
 
t
h
e
 
p
h
a
r
m
a
c
i
s
t
.
 
'
E
t
c
.
'
 
i
s
 
i
n
t
e
n
d
e
d
 
t
o
 
i
n
c
l
u
d
e
 
o
t
h
e
r
 
s
a
l
e
s
 
o
u
t
l
e
t
s
 
w
h
e
r
e
 
p
r
e
s
c
r
i
b
e
d
 
p
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
m
i
g
h
t
 
b
e
 
p
u
r
c
h
a
s
e
d
 
(
e
.
g
.
 
p
h
a
r
m
a
c
i
e
s
 
f
o
r
m
i
n
g
 
p
a
r
t
 
o
f
 
d
e
p
a
r
t
m
e
n
t
 
s
t
o
r
e
s
 
a
n
d
 
s
u
p
e
r
m
a
r
k
e
t
s
 
o
r
 
i
n
 
s
o
m
e
 
c
a
s
e
s
 
"
p
r
o
p
h
a
r
m
a
c
i
s
t
s
"
.
 
E
n
t
e
r
 
t
o
t
a
l
 
c
o
s
t
 
o
f
 
h
o
s
p
i
t
a
l
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
 
D
e
p
a
r
t
m
e
n
t
 
(
S
t
a
f
f
 
C
o
s
t
s
 
a
n
d
 
O
v
e
r
h
e
a
d
s
 
a
s
 
w
e
l
l
 
a
s
 
s
u
p
p
l
i
e
s
)
 
s
u
p
p
l
y
i
n
g
 
b
o
t
h
 
i
n
-
p
a
t
i
e
n
t
s
 
a
n
d
 
o
u
t
-
p
a
t
i
e
n
t
s
.
 
V
o
l
u
n
t
a
r
y
 
a
n
d
 
C
o
m
p
u
l
s
o
r
y
.
 
I
n
c
l
u
d
e
s
 
a
 
H
e
a
l
t
h
 
S
e
r
v
i
c
e
.
 I
I
.
 
N
A
T
I
O
N
A
L
 
B
A
C
K
G
R
O
U
N
D
 
D
A
T
A
 
C
u
r
r
e
n
t
 
P
r
i
c
e
s
.
 
C
u
r
r
e
n
c
y
 
U
n
i
t
 
•
.
.
 
(
m
i
l
l
i
o
n
s
,
 
b
i
l
l
i
o
n
s
,
 
e
t
c
.
)
.
 
6
 
7
 
Y
e
a
r
 
T
o
t
a
l
 
C
o
s
t
 
o
f
 
H
e
a
l
t
h
 
S
e
r
v
i
c
e
s
 
M
i
d
-
Y
e
a
r
 
P
o
p
u
l
a
t
i
o
n
 
N
a
t
i
o
n
a
l
 
A
c
c
o
u
n
t
s
 
P
r
i
c
e
 
I
n
d
e
x
e
s
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
T
o
t
a
l
 
T
o
t
a
l
 
C
o
v
e
r
e
d
 
b
y
 
G
N
P
 
N
I
 
G
e
n
e
r
a
l
 
P
h
a
r
m
a
c
e
u
t
i
c
a
l
s
 
I
n
c
.
 
T
a
x
 
E
x
c
.
T
a
x
 
H
e
a
l
t
h
 
I
n
s
u
r
.
 
r
e
t
a
i
l
 
(
a
)
 
(
b
)
 
(
a
)
 
(
b
)
 
(
a
)
 
(
b
)
 
(
a
)
 
(
b
)
 
1
9
6
6
 
1
9
6
7
 
1
9
6
8
 
1
9
6
9
 
1
9
7
0
 
1
9
7
1
 
1
9
7
2
 
1
9
7
3
 
1
9
7
4
 
1
9
7
5
 
1
9
7
6
 
E
s
t
.
 
1
9
7
7
 
P
r
o
j
.
 
1
9
7
8
 
P
r
o
j
.
 
1
9
7
9
 
P
r
o
j
.
 
1
9
8
0
 
P
r
o
j
.
 
D
e
f
i
n
i
t
i
o
n
s
 
:
 
C
o
s
t
 
o
f
 
H
e
a
l
t
h
 
S
e
r
v
i
c
e
s
 
R
u
n
n
i
n
g
 
C
o
s
t
s
 
o
n
l
y
 
(
E
x
c
l
u
d
i
n
g
 
C
a
p
i
t
a
l
 
a
n
d
 
D
e
p
r
e
c
i
a
t
i
o
n
)
.
 
H
e
a
l
t
h
 
I
n
s
u
r
a
n
c
e
 
G
N
P
 
T
o
t
a
l
 
c
o
s
t
 
w
h
e
t
h
e
r
 
p
a
i
d
 
f
o
r
 
b
y
 
G
o
v
e
r
n
m
e
n
t
,
 
H
e
a
l
t
h
 
I
n
s
u
r
a
n
c
e
,
 
C
h
a
r
i
t
y
 
o
r
 
t
h
e
 
P
a
t
i
e
n
t
.
 
V
o
l
u
n
t
a
r
y
 
a
n
d
 
C
o
m
p
u
l
s
o
r
y
.
 
I
n
c
l
u
d
e
s
 
a
 
H
e
a
l
t
h
 
S
e
r
v
i
c
e
.
 
G
r
o
s
s
 
N
a
t
i
o
n
a
l
 
P
r
o
d
u
c
t
.
 
N
a
t
i
o
n
a
l
 
I
n
c
o
m
e
.
 
P
r
i
c
e
 
I
n
d
e
x
 
(
e
s
)
 
E
x
p
l
a
i
n
 
i
n
 
a
 
b
r
i
e
f
 
n
o
t
e
 
h
o
w
 
i
n
d
e
x
 
i
s
 
c
o
n
s
t
r
u
c
t
e
d
.
 III.  FOREIGN  TRADE  OF  PHARMACEUTICALS 
SEnter  Totals where  breakdown  not  available). 
For  1975  or  last available Year.  Specify  Year  •..  (If possible  give  figures 
for  1970). 
Home  Production  Total 
Raw  materials 
Final Products 
Exports  to  EEC  to  non-EEC 
(free  on  board)  countries 
Raw  materials 
Final  products 
Total Exports 
Imports  from  EEC  from  non-EEC 
(cost  insurance  freight)  countries 
Raw  materials 
Final  products 
Total  Imports 
Net  home  consumption 
(factory prices) 
Definitions  : 
Raw  materials  and  final  products  : 
Give,  if possible,  an estimate  of  quantities  for  human  consumption. 
Final  products 
Pharmaceutical products  ready  to use. 
90 IV.  A.  What  do  you  considerer  to be  the main  reasons  for  the  change  in 
Consumption  indicated  in Table  1  above  ? 
B.  Is it possible  to  indicate quantitatively what  proportion of  the 
change  in Consumption was  due  to  specific factors  ?  Give  information 
where  available,  as,  for  instance,  any  modification concernine  scope 
of  social  security,  demographic  changes,  new  regulations. 
V.  PHARMACEUTICAL  CONSUMPTION  BY  HEALTH  INSURANCE  (VOLUNTARY  AND 
COMPULSORY)  OR  HEALTH  SERVICES 
Prescriptions provided  outside Hospital  Only 
--·--- Percentage Proportion of  Average  number  Average  number  Proportion of 
of  consultations  of  prescription of prescription expenditure 
population  (or visits)  forms  for  items  per  paid  by health 
Year  covered  leading  to  person  covered  prescription  insurance 
one  or more  form  % 
prescriptions  (outside 
hospitals) 
1966 
1967 
1968 
1969 
1970 
1971 
1972 
1973 
1974 
1975 
Add  any  comments  to explain the  trends  indicated  above. 
91 VI.A.  GIVE,  WHERE  POSSIBLE,  FOR  LAST  AVAILABLE  YEAR,  BREAKDOWN  OF  VALUE 
AND  NUMBER  OF  MEDICINES  PRESCRIBED  ISSUED  UNDER  COMPULSORY  AND 
VOLUNTARY  HEALTH  INSURANCE  (OR  HEALTH  SERVICE),  BY  : 
a)  Age  Groups  (1)  and  Number  of Persons  covered  in those  age 
groups. 
b)  Social  Classes  and  Number  of Persons  covered  in those  social 
classes. 
c)  Family  Size  and  Number  of  Families  covered  by  size. 
d)  Therapeutic  Category  (2). 
B.  LIST  THE  TEN  PRODUCTS  WITH  THE  LARGEST  SALES  IN  VALUE  UNDER  HEALTH 
INSURANCE  (COMPULSARY  AND  VOLUNTARY)  OR  HEALTH  SERVICE  IN  THE  LAST 
YEAR  WHERE  FIGURES  ARE  AVAILABLE. 
C.  TOTAL  NUMBER  OF  PHARMACEUTICAL  PRESENTATIONS  AVAILABLE  ON  THE  MARKET. 
TOTAL  NUMBER  OF  PHARMACEUTICAL  PRESENTATIONS  THAT  COULD  BE  PAID  BY 
HEALTH  INSURANCE. 
(1)  For  instance  :  from  0  to  5  years;  from  6  to  20  years;  from  21  to  60 
years;  more  than  60  years. 
(2)  Mr  ROBERT  prepared  a  list of  18  therapeutic  categories  (antibiotics, 
sedatives,  barbiturates, etc.). 
It is  possible  to  give  a  percentage  of consumption  for  each  category. 
92 PART  TWO  - POLICIES  OF  THE  MEMBER  STATES 
(Where  applicable  answer  questions  in terms  of  the  experience  of  the  period 
1966-1975.  Point  out  any modification observed  during  this period  or  any 
draft legal modification). 
VII.  ADMINISTRATION  BY  PUBLIC  AUTHORITY  OF  THE  MARKETING  OF  PHARMACEUTICALS 
A.  Regulation  of  sales 
1)  What  Organization is  empowered  to decide what  pharmaceuticals  can 
legally be  marketed  ? 
2)  What  criteria are  used  (e.g.  safety,  efficacy,  quality)  and  have 
these  criteria been  changed  in the  review period  ? 
3)  In which  year was  the  present  system of  regulation using present 
criteria introduced  ? 
4)  Was  it applied  only  to  new  products  ?  If  so,  are  there  plans  to 
apply  the  system  to  old  products  ? 
5)  Follow-up  given  to  the  three EEC  Directives. 
b)  ~~g~1~!~~~-~i-~~1~~-£E_~~E£~~~~~ by  Health  Insurance  Organisations 
(or Health  Service) 
1)  Is  there  a  restricted list of  pharmaceuticals which will be  paid 
for  (in whole  or part)  by health  insurance  for  use  outside 
hospital  ? 
IF  SO  : 
2)  What  criteria are  used  to  decide what  products  are  admitted  to 
the  list ?  Do  they  include 
i)  Medical  Criteria ? 
ii)  Economic  Criteria  (Price)  ? 
93 3)  What  criteria are  used  to  remove  a  product  from  the  list ? 
Do  they  include  : 
i)  Quantity  Sold  ? 
ii)  Excessive  Price 
iii) Failure  to  make  adequate  provision  for  research 
iv)  Implications  for  International Trade 
- licence  sales 
- imports  and  exports. 
B.  Economic  controls 
a)  Production 
l)  Do  pharmacists  have  a  monopoly  of  production in the  pharmaceutical 
industry  ? 
2)  Are  there  obstacles  to  the  establishment  of  firms  which  are  under 
the  financial  control  of  firms  with headquarters  located  outside 
the  EEC  ? 
c)  Distribution 
1)  Elements  of Monopoly  : 
i)  Have  pharmacists  the  monopoly  of  ownership  ? 
ii)  Have  pharmacists  a  monopoly  of  the retail  and  wholesale 
sale of  pharmaceuticals  ? 
iii)  Is it total  or  is it shared  by doctors  and  any  others  ? 
Specify. 
iv)  Can  certain or  all pharmaceuticals be  sold by  shops  not 
controlled  by  pharmacists  providing  they  employ  a 
pharmacist  ?  Specify whether  all or  some  pharmaceuticals. 
v)  Can  a  shop  which  sells pharmaceuticals  sell other 
products  If  so,  what  products  ? 
2)  Conditions  of Establishnent 
i)  Is  there  control  over  the  number  of  shops  or  outlets  of 
retail pharmacists  ? 
94 ii)  If  so,  what  criteria are  used  to  control  this  limitation 
(excluding  the  setting-up  of  non-profit-making 
pharmacies)  ? 
iii)  How  many  shops  or  outlets were  there  per million 
population  (excluding hospital  pharmacies)  at  last year 
when  figures  available  ?  Specify.  What  has  been  the 
trend  over  the  review  period  ? 
iv)  Exceptions  for  non-profit-making  pharmacies  (e.g.  hos-
pitals,  dispensaries  owned  by  sickness  funds,  mutual 
societies)  ?  Specify. 
3)  Regulations  for  the  purchase  of  goodwill  : 
i)  profit-making  ownership  (appropriation) 
ii)  non-profit-making  ownership 
- hospital  pharmacies, 
-mutual societies, 
- others. 
95 VIII.  PRICES 
A.  Production 
IF  SO 
1)  By  what  agency  ? 
2)  Using  what  criteria ? 
3)  What  is, if it exists,  the  permitted  percentage in the 
breakdown  of  the prices  ? 
4)  If  there  is  a  revision of  the prices,  what  rules  govern  the 
revision  ? 
5)  What  are  the  general  effects  of  the  system of  price 
regulation  (e.g.  increasing or  reducing prices)  ? 
6)  During  the review period  has  there  been  one  or more  price 
freeze  which  has  been  applied  to pharmaceuticals  ?  Specify. 
7)  During  the  review period  have  there been provisions  under 
which  firms  could  be  required  to pay  back excessive profits 
to health  insurance  organisations  (or  the health  service) 
and  if  so has  use  been made  of  these  provisions  ? 
8)  Is it allowed  for  a  firm  to  give  a  quantitative discount  to 
retail pharmacies  ? 
1)  Administrative  costs. 
2)  Manufacture(including  transport  and  the  cost of  imported 
raw  materials)  and  packaging. 
3)  Research  and  Development. 
4)  Patents  and  Licences. 
5)  Sales  Promotion. 
6)  Profit. 
(If  a  breakdown  of  receipts  is-not  available  in this  form  give 
whatever  breakdown is  available). 
96 B.  Importation 
a)  Are  there  special regulations  to set  up  prices  of  imported 
pharmaceuticals  ? 
IF  SO  : 
b)  Are  there  special discrepancies  for  nonEEC  countries? 
c)  What  about  the  setting up  of prices  for  such  products  ? 
d)  General  considerations  on  importation policy  (distinguish 
clearly,  if possible,  pharmaceuticals  imported  after packaging 
and  raw materials  imported before  packaging  in the  consumer 
country). 
C.  Distribution 
1)  What  is  the  average margin  in the wholesale  price  ? 
2)  Is  there  regulation of wholesale  margins  ? 
IF  SO  : 
3)  By  what  agency  ? 
4)  With what  effects  ? 
b)  Retail 
1)  What  is  the  average  margin  in  the  reta~l price  ? 
2)  Is  there  regulation of  retail margins  ? 
IF  SO  : 
i)  By  what  agency  ? 
ii) Explain  current regulation. 
iii) With what  effects  ? 
3)  Are  there  any  special honoraria paid  to  pharmacists  ? 
Specify. 
4)  Are  'hidden'  advantages  provided  by manufacturers  ? 
Specify. 
97 5)  During  the  review period  have  there  been provisions  under 
which wholesalers  could  be  required  to  repay  excessive 
profits  to  health  insurance  organisations  (or  NHS)  and  if so 
has  use  been made  of  these  provisions  ? 
D.  Taxation 
a)  Are  national  indirect  taxes  (e.g.  VAT)  levied  on  all or  some 
pharmaceuticals  ?  If  so,  at what  rate  or  rates  ? 
b)  Are  there  local  indirect  taxes  levied  on  all or  some 
pharmaceuticals  ?  If so,  at what  rate  or  rates  ? 
98 IX.  REGULATION  OF  CONSUMPTION 
A.  The  doctor 
IF  SO  : 
1)  Who  does  the  regulation or  inspection  ? 
2)  How  does  it operate  ? 
3)  Are  there  sanctions  ?  If so,  what  By  whom  ? 
B.  Sales  promotion 
a)  Is  there  control  of  the  quality  of  sales  promotion material 
1)  Sent  to doctors  ? 
2)  In advertisements  1n  journals  ? 
IF  SO  : 
3)  Who  operates it ? 
4)  How  does  it operate  ? 
b)  Is  there  any  restriction on  the activities  of  representatives  of 
firms  who  visit doctors  ?  If so,  specify  the  control  and  how  it 
is  policed. 
c)  Is  there  any  restriction on  hospitality provided  to  doctors  by 
firms  ?  If so,  specify. 
d)  Is  there  any  restriction on  the  sending  of  samples  of  products 
to  doctors  ?  If  so,  specify. 
e)  Is  there  any  control  of  the  quantity of  sales  promotion  activity 
undertaken by  firms  ?  (for  instance  provisions  for  limiting  the 
number  of  samples). 
C.  The  pharmacist 
a)  Is  there  any  restriction on  the  quantity,  the  duration or  the 
renewing  of  a  prescription which  a  pharmacist  may  dispense  under 
health  insurance  (or  the  NHS)  ? 
99 b)  Is  the  pharmacist  expected,  required,  or  allowed  to dispense 
cheaper  substitutes for  what  the  doctor  prescribes  in any  cases  ? 
If so,  specify. 
D.  The  patient 
a)  Financial 
1)  Is  there  legal provision  to  control  the  prices  charged  to  the 
public by retail pharmacies  ?  If so,  specify. 
2)  Explain  the  charges  (flat rate or  percentage)  falling on  the 
patient  under  health  insurance  (or  the  NHS).  Are  there 
variations  by  type  of  product  ? 
3)  Is it forbidden  for  the  patient  to  take  out  private insurance 
against  that part of  the  cost  of pharmaceuticals  which  the 
patient is  expected  to  pay  under  health  insurance  (or  the  NHS)  ? 
4)  i)  Does  health  insurance  (or  the  NHS)  pay  the  retail 
pharmacists  directly for  all or part of  the  cost of 
pharmaceuticals  ? 
If  so,  specify. 
If not 
ii)  Is it forbidden  to  do  so  ? 
Are  there  principles  to  take  into account  or  lay  down  to  limit 
the  number  or  type  of  products  which  can be  obtained without 
prescription  ? 
If  so,  specify. 
100 X.  THE  EFFECTS  OF  REGULATION 
A.  Economic  effects 
1)  Does  the  regulation of prices have  effects  on  exports  and 
imports  ?  If so,  specify. 
2)  Do  regulations  of  health insurance  have  effects  on exports  and 
imports  ?  If  so,  specify. 
3)  Do  regulations  of  safety  and  efficacy have  effects  on exports 
and  imports  ?  If so,  specify. 
1)  Has  the  average  income  per  capita of retail pharmacists 
increased more  or  less  than average  incomes  over  the  review 
period  ? 
2)  Have  the  pharmacists'  earnings  per  capita increased  more  or 
less  than earnings  of  similar  liberal occupational activities 
(for  example,  doctors,  architects,  etc.). 
What  effects does  the  regulation of  pharmaceuticals have  on 
employment  : 
1)  In manufacturing  ? 
2)  In wholesale distribution ? 
3)  In retai  1 distribution  ? 
Please  specify what  the national  trends  relating to  employment 
policy are  and  try  to discern what  the relationship is between 
these  policies  and  pharmaceutical  production  and  consumtion  (1). 
(1)  Give  also statistical figures  on 
i)  number  of  laboratories 
ii)  personnel  of  laboratories 
iii)  number  of wholesalers 
iv)  personnel  of wholesale distribution 
v)  number  of  pharmacies 
vi)  personnel  of  pharmacies 
vii)  trends  in consumption between  1970  and  1975. 
101 What  effects does  regulation have  on  tax revenue 
1)  From  industry  ? 
2)  From distribution ? 
1)  How  does  regulation affect  the proportion of  sales  (1)  in your 
country  from  foreign-controlled  firms  ? 
2)  How  does  regulation affect  the  proportion of  sales  (1)  in your 
country  from nationally controlled  firms  ? 
3)  What  proportion of  capital  employed  over  the  review  period has 
been financed  by  : 
i)  Other  countries  in the  EEC  ? 
ii)  Other  countries  outside  the  EEC  ? 
B.  Effects  on  health 
a)  Does  clinical freedom  have  adverse health  consequences  ? 
How  serious  is  this  problem  ? 
b)  Does  the  right of  the public  to purchase  pharmaceuticals without 
prescription have  adverse  health  consequences  ?  How  serious  is 
this  problem  ? 
XI.  CONCLUSIONS  (ad  libitum) 
(1)  Sales  of  final  products  and  raw materials. 
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